Podcasts about BioSystems

University College Dublin (UCD) and Teagasc have today announced that applications are now open for the second Food and Agriculture Sustainable Technology Innovation Programme (FAST-IP) which begins this September. FAST-IP, a specialist agrifood technology innovation programme, provides participants with the skills necessary to evaluate, select and validate ideas for new products and services in the agrifood sector and to accelerate the commercialisation pathway of these ideas. Aligned with Ireland's national agrifood strategy, Food Vision 2030, FAST-IP also aims to support establishing Ireland as a leader in sustainable food systems by balancing climate-smart agriculture, environmental and economic sustainability, and innovation. Participants on the inaugural programme, which ends in August, are currently developing business plans for new market ready innovations in areas ranging from soil health, food allergens, pest control and bioeconomy. Twelve (12) places are available on the full-time, 12-month, in-person programme aimed at mid-career professionals, which is delivered by the UCD School of Biosystems and Food Engineering in partnership with Teagasc at the AgTechUCD Innovation Centre at UCD Lyons Farm in Co. Kildare. FAST-IP provides participants with a €38,000 tax-free scholarship during the programme. Edel Mitchell, Programme Manager, FAST-IP, said, "We are delighted to open applications for our second FAST-IP programme. This is a wonderful opportunity for mid-career professionals to embrace their entrepreneurial ambitions and develop market led solutions to real problems experienced by the global agrifood sector. The practical needs led innovation process enables participants to deep dive and forensically understand pressing challenges for the agrifood sector and build innovative solutions. If you are interested in embarking on this journey and leveraging the unparallelled access to industry experts, mentorship and cross sectoral immersive opportunities I would encourage you to apply for the FAST-IP programme." FAST-IP uses design-thinking methodologies and has a practical focus. Through the programme participants, working in teams, learn how to conduct needs-led innovation to develop market validated solutions to unmet needs in the areas of agricultural technology and food sustainability sectors. Participants also spend 8-10 weeks immersed in agricultural environments including farms, food processing companies, and Teagasc locations throughout the 12-month programme. Dr Siobhán Jordan, Head of Technology Transfer and Commercialisation, Teagasc, said, "FAST-IP aims to position Ireland as a global innovator in AgTech and food systems by fostering the creation of high-potential start-ups, scalable businesses and sustainable solutions that address challenges in areas including, climate change, food security, productivity and economic diversification. We are now seeking applications from mid-career individuals who are interested in embarking on this cutting-edge, immersive programme to create innovative, sustainable agri-food solutions with expert mentorship and entrepreneurial training by UCD and Teagasc." FAST-IP is accredited by UCD at Level 9 on the National Qualifications Framework and participants who complete the programme will be awarded a Graduate Diploma in Agrifood, Innovation and Entrepreneurship. Professor Nick Holden, Professor of Biosystems Engineering in the UCD School of Biosystems and Food Engineering is the Academic Director of the Graduate Diploma Programme. The FAST-IP programme, running until the end of 2029, forms part of Enterprise Ireland's Innovators' Initiative which is co-funded by the European Regional Development Fund (ERDF) and the Department of Enterprise, Trade and Employment. UCD and Teagasc have strong reputations for academic and research excellence in the areas of Sustainable Food Systems, Agriculture, and Food Science, and are utilising their extensive networks, connections, domain ...

In this data-driven episode of Ecosystemic Futures, host Marco Annunziata interviews Dr. Tiffany Vora, a molecular biologist, Singularity Fellow in Biotechnology, and Vice President for Innovation Partnerships at ExploreMars. Drawing from her background in pharmaceutical research, teaching at Stanford University, and extensive work in space innovation, Dr. Vora examines how synthetic biology advancesthe development of specialized biosystems for space exploration. The discussion explores her recent publication "Space Synthetic Biology: A Paradigm for Sustainability on Earth and Beyond," detailing how technological convergence enables us to read, write, and engineer the source code of life with unprecedented precision. Dr. Vora presents research on how advanced biosystems can solve critical space exploration challenges through on-demand manufacturing of medicines, materials, and food.The episode offers actionable insights for leveraging genetic chassis organisms, flight-tested hardware for biological manufacturing, and shelf-stable reagents that deliver value for space missions and remote Earth locations. Dr. Vora outlines how these advanced biosystems can form the foundation of circular economies in space habitats where waste becomes valuable feedstock for new biological production cycles.HighlightsDNA as Programming Language: Life on Earth stores information as A, C, T, and G—a biological code we can now read, write, and edit with precision for space applications.Advanced Genetic Chassis: Researchers are developing customizable biological platforms that can be optimized for Mars's unique conditions, including radiation, salinity, and reduced light.Space Bioeconomy: "Making it" versus "taking it"—creating on-demand medicines, materials, and food in space solves critical up-mass constraints for long-duration missions.Extremophile Inspiration: Organisms that thrive in nuclear waste, salt flats, and other extreme Earth environments provide genetic blueprints for space-hardy biological systems.Flight-Tested Biomanufacturing: Developing hardware that enables small-batch, reproducible biological manufacturing in space environments has applications for both Mars missions and remote Earth locations.Circular Biosystems: Engineering biological processes where waste becomes feedstock for new materials and creates sustainable closed-loop systems essential for long-duration space habitation.Join us for this exceptional discussion. Guest: Dr. Tiffany Vora, Singularity Fellow in Biotechnology, and Vice President for Innovation Partnerships at ExploreMarsHost: Marco Annunziata, Co-Founder, Annunziata + Desai PartnersSeries Hosts: Vikram Shyam, Lead Futurist, NASA Glenn Research CenterDyan Finkhousen, Founder & CEO, Shoshin Works

Hello there!In this special rerun episode of The Crop Science Podcast Show, we revisit the world of high-tech agricultural machinery and the implications of the technological revolution on the agricultural industry. Dr. John Fulton discusses Ohio State's commitment to precision agriculture and its far-reaching impact on farming, both in Ohio and beyond. He explores how tractor technology has transformed from being merely a necessity to becoming a significant method for increasing planting efficiency. Covering everything from soil-to-tire interaction implications on tractor propulsion to the pioneering adoption of track systems, this episode is a must for anyone interested in the intersection of engineering, agronomy, and farming. Tune in to catch these insights again!"Automation in farming is about doing more with less, efficiently and sustainably."Meet the guests: Dr. John Fulton is a Professor and State Extension Specialist at The Ohio State University, leading efforts in machinery automation and digital agriculture. With a Ph.D. in Biosystems and Agricultural Engineering from the University of Kentucky, Dr. Fulton has over 20 years of experience in precision agriculture. His work focuses on integrating new technologies to enhance crop production efficiency and sustainability. As the President of the International Society of Precision Agriculture, Dr. Fulton is a key figure in advancing agricultural practices globally.What you will learn:(00:00) Highlight(01:13) Introduction(04:04) University experience and precision ag program(10:20) Digital agriculture and tech convergence(13:51) Discussion on engineering in agriculture(21:52) Tech in planters and sprayers(30:50) Nitrogen and phosphorus management(36:43) Final three questionsThe Crop Science Podcast Show is trusted and supported by the innovative companies:- CNH Reman- KWS

In this episode of BioPod's entrepreneurship series, Keshav talks with Dr. Alex Speakman about his entrepreneurial journey of starting E.V.A Biosystems. Alex talks about the help and resources available to aspiring entrepreneurs to turn their ideas into successful startups. He also provides helpful information on navigating through the various stages of a startup including ideation, validation and patenting.  Interviewed by Keshav, edited by Evangelia, art by Amandine and produced by Keshav. 

University College Dublin (UCD) has announced that fifteen participants have been selected for a new specialist food and agriculture entrepreneurship programme being delivered by the UCD School of Biosystems and Food Engineering in partnership with Teagasc. The announcement was made in Enterprise Ireland's Innovation Arena at the 2024 National Ploughing Championships in Ratheniska, Co. Laois, and was attended by Peter Burke TD, Minster for Enterprise, Trade and Employment. Peter Burke TD, Minster for Enterprise, Trade and Employment, said, "I would like to take this opportunity to congratulate the fifteen participants who have been selected to take part in the inaugural 12-month Food and Agriculture Sustainable Technology Innovation Programme or FAST-IP. The ambition of FAST-IP is to drive innovation in Ireland's food and agricultural sector by supporting needs-led innovation, creating start-ups with the capability to scale and sell internationally, and generating new jobs for the sector in Ireland. I wish the participants every success in the year ahead." FAST-IP will further enhance innovation in the food and agri sector by providing programme participants with the necessary skills to evaluate, select and validate ideas for new products and services in this sector and to accelerate the commercialisation pathway for the identified products and services. FAST-IP is currently underway at the AgTechUCD Innovation Centre at UCD Lyons Farm in Co. Kildare and will be delivered annually until the end of 2029. FAST-IP is accredited by UCD at Level 9 on the National Qualifications Framework and participants who complete the programme will be awarded a Graduate Diploma in Agrifood Innovation and Entrepreneurship. Professor Kate Robson Brown, UCD Vice-President for Research, Innovation and Impact, said, "We were delighted to receive nearly 200 applications for FAST-IP's inaugural programme which is a strong indication of the demand for this exciting Innovators' Initiative programme from across Ireland and indeed internationally. I would especially like to congratulate the fifteen participants who have been selected for the first programme following a rigorous interview process and I wish them every success over the coming year. During the next year the participants will work together to discover real world needs in the food and agricultural sector through their immersive experiences in industry environments and bring innovative solutions to address the identified needs in a commercially viable manner with the aim of creating start-ups and generating new jobs." Participant Brian Russell, Maynooth, Co. Kildare, said, "I am excited to be accepted as a participant in the first year of the FAST-IP programme. As I change my career trajectory the programme provides me with a unique opportunity to bring my experience from manufacturing, project management and quality, into a diverse team driving sustainable technology and innovation in the Food and Agriculture sector, turning transformative ideas into viable business propositions. With most of my career having been overseas, the contact network that the programme offers, meeting, learning and collaborating with industry leaders and experts is an incredibly resource to be part of." FAST-IP uses design-thinking methodologies and has a practical focus. Through the programme, participants will learn how to conduct needs-led innovation to develop market-validated solutions to unmet needs in the areas of agricultural technology and food sustainability sectors. Participants will also spend 8-10 weeks immersed in agricultural environments, including farms, food processing companies and Teagasc locations throughout the programme. Professor Frank O'Mara, Teagasc Director, said, "The world leading research, expertise and facilities from the UCD and Teagasc partnership and supporting industry networks, will demonstrate the breadth and depth of the agri-food sector to the participants. We look forward to...

On this episode of The Water Table podcast, Jamie sits down with Dr. Ehsan Ghane of Michigan State University to talk about the recent US Census which is reporting a decrease in acreage with tile drainage across the Midwest. Are the numbers accurate, or is there more at play? And while we're on the subject of numbers, learn why long term is better for agricultural research. Chapters & Episode Topics: 00:00   Today on TWT00:14   Welcome Dr. Ehsan Ghane01:07   Pipe perforations, an update02:40   When will we see results?03:30   Census numbers – are they crazy?05:12   Data gathering06:00   Very surprising numbers07:20   An educated guess08:20   Huge uncertainty in the data09:15   A drop in responses11:00   Conservation drainage and phosphorus12:20   It's so variable13:40   Saturated buffers14:40   Lowering blooms in Lake Erie15:15   Long-term is key16:17   Seven years and counting16:45   What has changed?18:00   To the extremes19:15   The last word – tools for specific farmsAbout the Guest: Dr. Ehsan Ghane teaches Biosystems and Agricultural Engineering at Michigan State University, along with performing extensive research into drainage pipe pattern and style, and how those things play into increased water quality and crop yield. He holds a Ph.D. from Ohio State University and spent time at the University of Minnesota in the department of Soil, Water and Climate.Related Content: 2022 Ag Census Reveals Surprising Trend in Acreage of Tile Drainage in the MidwestMichigan State University Biosystems & Agricultural Engineering - DrainageEpisode #78: Put A Sock On It?Find us on social media! Facebook Twitter InstagramListen on these Podcast Platforms:Apple Podcasts Spotify Visit our website to explore more episodes & water management education

Michigan State University is racing into the future by participating in the Indy Autonomous Challenge, which officially launched in 2019 and brings together academic institutions and public-private partnerships to challenge university students from across the globe to invent and test a new generation of automated vehicle software to operate fully autonomous race cars.  Discussing MSU's role in the challenge in this episode of MSU Today are MSU Mobility Director Judd Herzer and Daniel Morris, associate professor in the departments of Biosystems and Agricultural Engineering and Electrical and Computer Engineering at MSU, who will lead a technical team from MSU. Conversation Highlights: (0:27) – Morris on his research interests. (1:34) – Herzer on the evolution of his role as mobility director and the history, mission, and evolution of the challenge. (3:13) – Morris on what excites him about participating in the challenge. (4:17) – How do you compare the decisions a driver has to make in an Indy car to those same decisions the autonomous software must make? (8:30) – Is the goal of participating in the challenge to inform MSU's overall work in mobility?  (12:39) – What races are coming up? How have we been doing in competitions so far? How cool is it to watch the cars race in the dark? (15:37) – What happens if GPS or the internet goes down? (16:23) – “The MSU team holds the current Guinness World Record for land speed achievement for an autonomous vehicle. It goes 192.2 mph.” The team is seeking industry or individual partners who are interested in supporting the team's endeavors. (18:01) – Where are we going? What's ahead as the autonomous space evolves? How will our students be involved in autonomy's future? (20:45) – “The Indy Autonomous Challenge is a unique research platform, an incredible experiential learning experience for our students, and a great way for MSU Mobility to expand its partnerships within industry to help develop the future of automated and connected vehicle technologies and do it one of the most cool, extreme, and fascinating ways.” Listen to “MSU Today with Russ White” on the radio and through Spotify, Apple Podcasts, and wherever you get your shows.

University College Dublin (UCD) today announced that applications are now open for a new food and agriculture innovation and entrepreneurship training programme, commencing this September, to be delivered by the University in partnership with Teagasc. There are only fifteen (15) places available on the 12-month, in-person Food and Agriculture Sustainable Technology Innovation Programme (FAST-IP), which is aimed at mid-career professionals. FAST-IP will provide participants with a €38,000 tax-free scholarship during the programme. The goal of FAST-IP is to further enhance innovation in the food and agricultural sector by providing programme participants with the necessary skills to evaluate, select and validate ideas for new products and services and to accelerate the commercialisation pathway. FAST-IP will use design-thinking methodologies and will have a practical focus. Through the programme, participants will learn how to conduct needs-led innovation to develop market-validated solutions to unmet needs in the areas of agricultural technology and food sustainability sectors. Participants will also spend 8-10 weeks immersed in agricultural environments including farms and food processing companies throughout the year long programme. FAST-IP is accredited by UCD at Level 9 on the National Qualifications Framework and participants who complete the programme will be awarded a Graduate Diploma in Agricultural Innovation and Entrepreneurship. FAST-IP will be delivered by the UCD School of Biosystems and Food Engineering, in partnership with Teagasc, at the newly opened AgTechUCD Innovation Centre at UCD Lyons Farm in Co. Kildare. Professor Nick Holden, Professor of Biosystems Engineering in the UCD School of Biosystems and Food Engineering, is the Academic Director of the Graduate Diploma Programme. Gary Ryan, Director, AgTechUCD, said, "The success of FAST-IP will depend to a great extent on attracting the right mix of high calibre individuals to the programme. FAST-IP is designed to cater for mid-career individuals who have accumulated significant professional experience to date and who are now interested in pivoting towards an entrepreneurial journey based on the development of an innovative technology that will support sustainable practices in the agricultural and food sectors. A fundamental underpinning of the programme is that participants will come to it with an open mind as to potential innovations and without any preconceived biases towards an existing idea that they might like to explore. The programme is based around discovering real world needs through exposure to industry environments in the agfood supply chain and bringing innovative solutions to bear on such needs in a commercially viable manner." He added, "I would encourage anybody meeting the programme criteria and with an interest in building a business that will deliver innovative solutions in support of sustainable agri and food sectors to engage with the process as early as possible. Interest is already high and is likely to build even further in the coming weeks." Dr Siobhán Jordan, Head of Technology Transfer and Commercialisation, Teagasc, said, "Enhancing entrepreneurship and innovation in the food and agricultural sector to deliver impacts nationally and globally requires multi-disciplinary approaches from engineering to marketing from food science to ICT. The FAST-IP programme delivered by UCD and Teagasc will enable participants to deliver new solutions for the longer term sustainability of the agri-food sector." UCD and Teagasc, with strong reputations for academic and research excellence in the areas of Sustainable Food Systems, Agriculture, and Food Science, will utilise their extensive networks, connections, domain expertise, entrepreneurial experience, and track-record for supporting, fostering and spinning out start-ups over the next 6 years of the programme. The AgTechUCD Innovation Centre, which is part of NovaUCD, is focused on promoting an...

Meet biosystems engineering sophomore Bella Nonales, a dean's list dynamo with a chance of making history as the drummiest major in the history of the Auburn University Marching Band. Not bad for someone who just celebrated her 5th birthday. 

In this very first episode of The Crop Science Podcast Show, we explore the world of high-tech agricultural machinery and the implications of the technological revolution on the Agricultural industry. We'll focus on Ohio State's commitment to precision agriculture and its impact on farming in Ohio and beyond. Here, Dr. John Fulton will explore how tractor technology has transformed from being merely a necessity to being a significant method for increasing planting efficiency. Discussing everything from soil-to-tire interaction implications on tractor propulsion to the pioneering adoption of track systems – this episode is a must for anyone interested in the intersection of engineering, agronomy, and farming."Automation in farming is about doing more with less, efficiently and sustainably." - Dr. John FultonWhat you'll learn:(00:00) Highlight(00:50) Introduction(02:50) University experience and precision ag program(09:50) Digital agriculture and tech convergence(13:27) Discussion on engineering in agriculture(21:29) Tech in planters and sprayers(23:52) AI in farm equipments and maintenance challenges(26:26) The changing technology in agriculture(30:30) Nitrogen and phosphorus management discussion(34:58) The impact and adoption of drone technology(36:41) Final questionsMeet the guest: With a BA in Physics from Wittenberg University and an M.S. and Ph.D. in Biosystems and Agricultural Engineering from the University of Kentucky, Dr. John Fulton stands at the forefront of agricultural innovation. As a Professor at Ohio State University and the President of the International Society of Precision Agriculture, he is a leading voice in the field, transforming how we approach farming through technology. His work symbolizes a bridge between traditional agricultural practices and the modern digital era.Connect with the guest!The Crop Science Podcast Show is trusted and supported by innovative companies like:- KWSAre you ready to unleash the podcasting potential of your company? wisenetix.co/custom-podcast

In this compelling episode, our director of education and host of Whole Grain, Jim Lenz welcomes Dr. Carol Jones, a distinguished figure in production agriculture and materials handling design. Dr. Jones shares her professional journey, including her role at GEAPS Exchange and the Fire Service Training Grain Entrapment Rescue program prior to the discussion on grain dust management.Overview of Grain Dust Management:Dr. Jones provides a comprehensive overview of the significance of grain dust in the context of grain elevators, addressing potential hazards and environmental concerns.Evolution of Dust Management Practices:Delving into her vast experience, Dr. Jones discusses the changing landscape of dust management practices over the course of her career.Safety Considerations:Emphasizing the importance of safety, Dr. Jones explores key safety considerations related to grain dust in grain elevators, including the risks of combustible dust.Regulatory Landscape:Dr. Jones sheds light on the regulatory framework surrounding grain dust management, discussing how regulations have evolved and impacted grain elevator operations.Technologies and Innovations:Exploring technological advancements, Dr. Jones shares insights into monitoring systems, ventilation, and other innovations for effective dust control.Education Initiatives:Highlighting the crucial role of education and training, Dr. Jones describes initiatives she's been part of and offers recommendations for industry professionals.Future Outlook:Dr. Jones speculates on the future of grain dust management, discussing emerging technologies and trends that may shape the industry.About the guest:Dr. Carol Jones, PE joined the Biosystems and Ag Engineering Department Faculty at Oklahoma State University in 2002 after a long career in production agriculture and materials handling design.  She is also an OSU alum with all of her degrees from OSU. She recently retired from her full-time professorship to work as an instructor with OSU's Fire Service Training Grain Entrapment Rescue program. Dr. Jones owns CL Jones Consulting LLC which provides grain handling and storage engineering, training and forensic services.Links:For a poignant real-life story related to grain entrapment rescue, revisit Episode 13: "Bring Them Home Safe: The Dawn Chisholm Story."Witness Dr. Jones facilitating a confined space rescue at GEAPS ExchangeLearn more about Dr. Carol Jones and her consultative services by visiting her LinkedIn pageGEAPS IS HOSTING THEIR ANNUAL GEAPS EXCHANGE CONFERENCE AT THE KANSAS CITY CONVENTION CENTER February 24th – 27th. LEARN MORE AT www.geaps.com/exchange.Grain Elevator and Processing Society champions, connects and serves the global grain industry and its members. Be sure to visit GEAPS' website to learn how you can grow your network, support your personal professional development, and advance your career. Thank you for listening to another episode of GEAPS' Whole Grain podcast.

In this episode of Life Science Success, my guest is Brian DeDecker.  Brian is the CEO and co-founder of Seedling Biosystems in Boulder, Colorado. The planet's ecosystems strain from current chemical and protein manufacturing methods and Brian co-founded Seedling to help solve this crisis. 

The agriculture sector has had to embrace adaptability and innovation as it navigates new technologies and the climate crisis. Today we're diving into agriculture and discovering how engineers are developing solutions for a better future in the sector. We hear about their impressive sustainability efforts and how AI and automation are playing an important role. Our experts today are Associate Professor and Vice Principal for Internationalisation in UCD College of Engineering & Architecture, Tom Curran, Mechanical engineer with Agrigear, Neil Pigott and Agricultural Inspector with the Department of Agriculture, Food and the Marine, Robert Leonard. THINGS WE SPOKE ABOUT01:12 How the Department Of Agriculture uses engineering 04:12 Engineering in agriculture machinery 07:30 Current research in agriculture 09:26 Application of robotics and automation 14:22 Collection and analysing data from farms 15:31 Smart farming 17:03 Adapting the farming industry to new tech21:40 The Ploughing Championships 23:01 Climate change challenges for the sector 24:48 Sustainability efforts in agriculture GUEST DETAILSTom Curran is an Associate Professor and Vice Principal for Internationalisation in UCD College of Engineering & Architecture. He leads the Horizon Europe project, BioBeo, on innovative education for the bioeconomy with 15 partners across 10 European countries. He is the Director of the UCD MSc Environmental Technology degree programme. His research interests include waste management and air quality. He is a graduate of UCD's Engineering programme, holding a BE (Ag & Food), MEngSc (Environmental Engineering) and a PhD in Biosystems Engineering. He worked in production and environmental management in the food industry for a number of years before joining as faculty in UCD School of Biosystems and Food Engineering.Website: https://people.ucd.ie/tom.curran Social Media: https://ie.linkedin.com/in/tompcurran Niall Pigott is a chartered engineer with extensive experience in mechanical design and manufacturing engineering, with strong quality compliance exposure. Comprehensive knowledge of Solidworks 3D CAD (computer aided design) and Lantek Expert CAM (computer aided manufacturing) software.Website: https://www.agrigear.ie/wheel-rim-manufacturing  Social Media: https://www.linkedin.com/in/niall-pigott-a5131638/ Robert Leonard holds an honours degree in Agricultural Engineering and a Masters in Mechanical Engineering.  He completed his PhD in UCD, the focus of which was looking at the development of decision support systems for spraying potatoes against late Blight and spray drift reduction techniques. Robert joined the Department of Agriculture, Food and the Marine in July 2002.  His role is to provide technical specifications, to support agricultural industries, that meet required standards (including legal) in respect of Construction, Health and Safety, Animal Welfare and the Environment. To promote and implement specific measures supporting environmentally sustainable agriculture and to provide specialist expertise to various divisions and offices that are charged with implementing schemes associated with grant aid for agricultural and forestry related industries.MORE INFORMATIONLooking for ways to explore or advance a career in the field of engineering? Visit Engineers Ireland to learn more about the many programs and resources on offer. https://www.engineersireland.ie/  Engineers Journal AMPLIFIED is produced by DustPod.io for Engineers Ireland.QUOTESThe research touches on the environmental impacts of the whole chain from the farm to the fork from getting the herbs out of the fields or foreign buildings, right through to processing of the food so that it's ready for consumers to eat in a safe manner, but also in the most sustainable way as well. - Tom Curran The applications of robotics within agricultural engineering is really in its genesis mode and this sort of engineering will blossom in the very near future. This technology will not take away people's jobs, but it will actually enhance people's jobs. - Niall Pigott There's a lot of technology coming from the fertilizer and pesticide application side looking at identifying weeds, diseases, and applying pesticide just to the points of where it's at using vision control. All that information can be fed into a higher level of AI to actually get them to understand what way to apply crops and to get the best return while having the least inputs. - Robert Leonard I think the farming community in general is quite adaptive, they have to be. - Niall PigottIn the future there's going to be a lot more robotic controls, but you need to be monitoring what's going on. It's not a case of just watching and letting the robots take over. The farmer needs to understand the information they're getting. - Robert Leonard Farming is such a long standing industry, we all need farmers to produce our food. It's like everything else, some people are resistant to change naturally. I grew up on a farm and I'm currently a part time farmer. Inspeaking to and engaging with farmers, a lot of farmers are probably the most innovative people I know - Tom Curran If we do a certain action, we have to take into account so many different factors; climate, nature, water, air, etc. This is a message I think that we need to communicate to the general public, how engineers and scientists are working to be more environmentally sustainable, but also to take into account changing weather patterns for the future. - Tom Curran KEYWORDS#engineering #farming #agriculture #machinery #sustainability #ploughingchampionships

Existing predictive models for drug behavior in the human intestine have been hit or miss, leading to unpredicted failure of drug development at the cost of billions. Altis Biosystems has developed a proprietary intestinal model with human stem cells that dramatically improves the predictive capability of drug effects and toxicity in the intestine and thus can substantially reduce the cost of drug development failure. CEO Ben Scruggs  has 16 of the top 20 Big Pharma companies as customers as the Altis human intestinal model dominates pre-clinical drug testing for intestinal effects and toxicity. (recorded 9/8/23)We invite your feedback and suggestions at ventureinthesouth.com or email david@ventureinthesouth.com. If you like the podcast, leave us a review and share with your friends! Follow David and Paul on LinkedIn to stay updated on the newest episodes. To learn more about the RollingSouth Funds, visit rollingsouth.vc or email david@rollingsouth.vc. Thanks for listening and remember: Our mission is to MAKE MONEY, HAVE FUN AND DO GOOD

Innovation plays a vital role in every industry, and the pet food sector is certainly no exception. One emerging technology that is rapidly gaining momentum in this field is High-Pressure Processing (HPP). This groundbreaking method is revolutionizing the preservation of raw pet food by extending its shelf life and enhancing food safety measures. In this episode, we had the privilege of hosting Dr. Mary-Grace Danao, a distinguished research associate professor specializing in Food Science and Technology with a focus on HPP in raw pet food. Dr. Danao shed light on the significance of HPP in ensuring the safety and quality of raw pet food. Additionally, she explored the growing market for raw pet food and emphasized the crucial need to maintain high-quality standards throughout the entire production process.“HPP technology involves using pressure instead of traditional temperature to process our foods, ensuring their safety." - Dr. Mary-Grace DanaoWhat you'll learn:(00:00) Highlight(01:26) Introduction  (03:47) Introduction to High-Pressure Processing (HPP)(05:44) Difficulty in inactivating spores(10:27) Shelf-life extension of fresh pet food by HPP(12:14) Factors influencing HPP protocol (19:27) Combining HPP with other methods(22:08) The challenge of achieving log reductions in ground meat(23:41) Use of HPP in the treat market(36:58) Final questionsMeet the guest: Dr. Mary-Grace DanaoExperience:Current: Research Associate Professor at the University of Nebraska-LincolnBackground:Ph.D. Biosystems and Agricultural Engineering (University of Kentucky)M.Sc. Biosystems and Agricultural Engineering (University of Kentucky)B.Sc. Agricultural and Biological Engineering (University of Florida)Connect with the guest!The Pet Food Science Podcast Show is trusted and supported by innovative companies like:- Wilbur-Ellis Nutrition- Kemin

Jamie is joined by Dr. Ehsan Ghane from Michigan State University, a professor and researcher, for a conversation about which type of pipe is best for specific types of soil. Should the pipe have narrow slots? Should it be wrapped in a sock? What is drainage intensity? Does water-main size matter? Dr. Ghane answers all of these questions and more. Don't miss this episode!Michigan State University Drainage:https://www.egr.msu.edu/bae/water/drainage/About the Guest:Dr. Ehsan Ghane teaches Biosystems and Agricultural Engineering at Michigan State University, along with performing extensive research into drainage pipe pattern and style, and how those things play into increased water quality and crop yield. He holds a Ph.D. from Ohio State University and spent time at the University of Minnesota in the department of Soil, Water and Climate.Episode Topics:00:00   Intro00:32   Today on The Water Table…01:13   Welcome to Dr. Ehsan Ghane02:07   Pipe style – all the innovations03:30   It's different in Michigan04:18   Perforation patterns and pipes05:45   Socks = speed07:50   Drainage intensity – what is it?09:29   What about a heavier soil?11:30   A soil bridge12:00   Drainage sedimentation tool13:00   More money or not?15:00   How to find the information15:20   Water quality and controlled drainage17:27   The “Main” thing20:00   Saving money could cost you later25:00   Just watch the video!28:00   Thanks for joining!Follow us on social media! Facebook Twitter Find us on Apple Podcasts Subscribe to our Spotify Listen on Google Podcasts Visit our website to explore more episodes & water management education:https://www.watertable.ag/the-podcast/ 

Stefano Zapperi is Professor of Theoretical Condensed Matter Physics and Coordinator of the Center for Complexity and Biosystems at the University of Milan. He graduated in physics at the University of Rome “La Sapienza” and received his Ph. D. in physics from Boston University. After a postdoctoral position at ESPCI in Paris, he became tenured researcher at INFM at the University Rome and then at the University Modena and Reggio Emilia. He has been invited as visiting scientist or visiting professor in many institutions worldwide. Prof. Zapperi is an expert in the statistical physics of complex systems and has fostered computational and data driven approaches to materials science and biophysics. His most notable contributions include the theory of the Barkhausen noise in magnets, the statistical physics of plasticity and fracture, and recent work on the physics of cancer and protein aggregation. Prof. Zapperi is the recipient of numerous awards including the Marie Curie Excellence Award. He was elected fellow of the American Physical Society and named Finland Distinguished Professor by the Academy of Finland. He organized several international workshops, summer schools and symposia on a variety of interdisciplinary research topics, ranging from the “Physics of Cancer” to Statistical Physics of Materials and Complex Systems. He has been elected member of the council and the executive committee of the Complex Systems Society and acted as chair of the steering committee of the Conference on Complex Systems. In 2018 he co-founded Complexdata alongside Caterina La Porta. Caterina La Porta is professor of General Pathology at the University of Milan where she coordinates the research group Oncolab and is member of the steering committee of the Center for Complexity and Biosystems. In 2018, she co-founded the startup ComplexData where she serves as CEO. During her scientific career, Prof. La Porta published more than 200 papers in international journals mainly on cancer and neurodegenerative diseases, receiving thousands of citations. In the past 15 years, she shifted her interest to quantitative biology and digital health. The focus of her current research activity focuses on understanding cancer heterogeneity using tools from cell biology, biophysics and data science. Her interdisciplinary view of cancer is summarized in a book published by Cambridge University Press in 2017 entitled “The Physics of Cancer”. Prof. La Porta was selected as one of the 100 most important female scientists in Italy (https://100esperte.it/) and was visiting scientist in many universities around the world, including MIT, Cornell University, Aalto University, Rice University, the ENS Paris, the Weizmann Institute of Science and LMU in Germany. Prof. La Porta has a long track record of public outreach activities, including the organization of several editions of the EU Researcher's night, and is involved in many other science dissemination activities.

Lay of The Land's conversation today is with Jan Jenson — PhD, CEO/CSO/Founder of Trailhead Biosystems, based here in Cleveland.Jan is the Lead Inventor of Trailhead Technology and has 20 years as a molecular developmental biologist. He is the Eddie J. Brandon Endowed chair of Diabetes Research at the Cleveland Clinic and obtained his Ph.D. from U. Copenhagen in 1998 and has been faculty at US institutions since 2001 where he has published more than 50 peer-reviewed papers and is now engaged with multiple research projects and consortia covering neural, renal, pancreatic areas, as well as cancer and immunotherapy.The technology of Trailhead Biosystems — which exists around the high-dimensional design of experiments dependent on computerized designs and robotic executions — allows for the production of cellular ink as the biological building blocks to address a myriad of issues across cell-based therapeutics, drug discovery, organ printing, and disease modeling — ultimately aiming to arrive at the cures for diseases we've only historically been able to treat like Diabetes, which is one of Jan's original motivations.Trailhead Biosystems is one of the most fascinating companies I've come across so far and I learned so much from this conversation with Jan — everything from the basics of cell differentiation and development biology, to the vast implications that unlocking industrialized manufacturing of specialized human cells can have for regenerative medicine! Please enjoy my conversation with Jan Jensen--Learn more about Trailhead BiosystemsConnect with Jan Jensen on LinkedIn--Connect with Jeffrey Stern on LinkedInFollow Jeffrey Stern on Twitter @sternJefeFollow Lay of The Land on Twitter @podlayofthelandhttps://www.jeffreys.page/

Tamer Mohamed of Aspect Biosystems joins Chris Hobbs this week for Episode 72 of the Afternoon "T" podcast. Join us while Tamer discusses how Aspect Biosystems is breaking ground in the treatment of diabetes (7:40), being humbled by the power of biology (53:00), and how "Unreasonable" (almost) tempted him to get a tattoo (50:00). We'll also hear from this week's "Startup we love" CTO Michael Sousa of SingleKey (26:40) who also chimes in with a question for Tamer about how soon we'll get to see some of Aspect Biosystems work in the world around us.

In questo episodio di Voices from the Labs annunceremo i risultati dell'ANA Avatar X Prize, la competizione mondiale tra avatar robotici a cui IIT ha partecipato con le uniche due squadre rappresentanti l'Italia: AlterEgo team e iCub team, inoltre racconteremo dell'arrivo del vettore Cygnus NG-18 sulla Stazione Spaziale Internazionale per la consegna di diversi esperimenti scientifici, tra i quali Prometeo, messo a punto da Gianni Ciofani del Centro IIT di Pontedera. Infine, in occasione della recente giornata internazionale del contrasto al traffico illegale dei beni culturali, ricorderemo i progetti del Center for Cultural Heritage Technology, il centro IIT a Venezia coordinato da Arianna Traviglia, impegnati proprio nell'individuare e contrastare le attività di saccheggio del patrimonio artistico.Per la consueta intervista ai microfoni di Voices From The Labs, converseremo con il ricercatore Massimo de Vittorio, PI del laboratorio centro Nanotechnologies for Humans and Biosystems e Coordinatore del Center for Biomolecular Nanotechnologies di IIT a Lecce. Il suo team collabora con personale clinico per costruire nuovi dispositivi per aumentare la comprensione su specifiche patologie, sia per intercettare precocemente i sintomi che per predire il decorso di una malattia. In questo contesto multidisciplinare hardware e software, elementi spesso contrapposti, sono entrambi fondamentali per sviluppare nuove tecnologie.

Vectus Biosystems (ASX: VBS) non-executive director Maurie Stang joins Small Caps to discuss the company's development of its lead cardiovascular drug VB0004. A phase 1a human safety trial was successfully completed in Melbourne in September and demonstrated an impressive safety record. The antifibrotic and antihypertension oral drug will move to the next phase of 1b testing and the company also plans to evaluate its impact in COVID-19 induced fibrotic damage. Articles:https://smallcaps.com.au/vectus-biosystems-phase-1b-drug-trial-treat-fibrosis-hypertension/https://smallcaps.com.au/vectus-biosystems-unveils-more-promising-results-phase-1-clinical-trial/ For more information on Vectus Biosystems:https://smallcaps.com.au/stocks/VBS/See omnystudio.com/listener for privacy information.

Vectus Biosystems: Could this drug eventually prevent thousands of deaths?  Listen to ASX-listed Vectus Biosystems CEO Karen Duggan talk to Matt Birney on the Bulls N' Bears Report about Vectus' rapidly developing treatment for a condition that is a factor in up to 40 per cent of all deaths.See omnystudio.com/listener for privacy information.

In the Horse Health Segment we talk barn air quality with Staci McGill, Spotlight Rider in the Beyond the Ribbons Series, 12 Year Old Eventer Keira, checks in with an update and some Weird News.  Listen in...HORSES IN THE MORNING Episode 2931 - Show Notes and Links:The HORSES IN THE MORNING Crew: Glenn the Geek:  co-host, executive in charge of comic relief, Jamie Jennings: co-host, director of wacky equestrian adventures, Coach Jenn:  producer, Chaos Control Officer.Title Sponsor: State Line TackImage Credit: Jamie JenningsGuest: Spotlight Rider in the Beyond the Ribbons Series, 12 Year Old Eventer, Keira O'Connor-ReichertGuest: Staci McGill, pursuing her Doctorate in Biosystems and Agricultural Engineering at UKThere's an App for that!  Download our FREE new Horse Radio Network App for iPhone and AndroidFollow Horse Radio Network on TwitterAdditional support for this podcast provided by: Daily Dose Equine, Wintec Saddles, and Listeners Like YouTime Stamps: 03:55 - Daily Whinnies28:15 - Staci McGill on Air Quality45:20 - Keira!56:02 - Weird NewsSupport the show

In the Horse Health Segment we talk barn air quality with Staci McGill, Spotlight Rider in the Beyond the Ribbons Series, 12 Year Old Eventer Keira, checks in with an update and some Weird News.  Listen in...HORSES IN THE MORNING Episode 2931 - Show Notes and Links:The HORSES IN THE MORNING Crew: Glenn the Geek:  co-host, executive in charge of comic relief, Jamie Jennings: co-host, director of wacky equestrian adventures, Coach Jenn:  producer, Chaos Control Officer.Title Sponsor: State Line TackImage Credit: Jamie JenningsGuest: Spotlight Rider in the Beyond the Ribbons Series, 12 Year Old Eventer, Keira O'Connor-ReichertGuest: Staci McGill, pursuing her Doctorate in Biosystems and Agricultural Engineering at UKThere's an App for that!  Download our FREE new Horse Radio Network App for iPhone and AndroidFollow Horse Radio Network on TwitterAdditional support for this podcast provided by: Daily Dose Equine, Wintec Saddles, and Listeners Like YouTime Stamps: 03:55 - Daily Whinnies28:15 - Staci McGill on Air Quality45:20 - Keira!56:02 - Weird NewsSupport the show

What’s a resilient biosystem? Healthy soil, healthy water, healthy cycles. They’re so key that even defence departments around the world are starting to invest in creating them, as research shows we have just 60 harvests left if we stick to our industrialised system of agriculture.There’s hope for us yet, and it lies in the soil. Microbiologist and regenerative agriculture expert, Walter Jehne, joins me to explain how soil can capture carbon, promote global cooling, and feed billions on very little space. He explains how politics got in the way of progress in the 70s, and why governments are scrambling to speak to him and his team. This is an utterly fascinating discussion (please bear with the lower quality recording). Walter was suggested by listeners so, please, if there is anyone you would like me to get on the show, don’t hesitate to reach out.Listen to the full interview here, catch it on on Apple or Spotify, or watch on Youtube. You’ll find the bonus episode on Youtube over the weekend, and paid subscribers have access to the interview transcript on Planet: Critical.© Rachel Donald Get full access to Planet: Critical at www.planetcritical.com/subscribe

Guest Bridget Hunter-Jones is the co-founder and CEO of Impact Biosystems, a venture-backed startup in the Boston area developing adaptive hardware and software solutions in the health and fitness space. Hunter-Jones leads a small, passionate, cross-functional team that wants to create a new personalized recovery market to support the at-home fitness phenomenon that accelerated during the COVID-19 pandemic. Impact Biosystems' goal is to make athletes of all varieties prevent injuries, perform at their peak, and uniquely live and feel better. The company's soon-to-launch Pact, which aims to compete with the likes of Theragun and other at-home massage products, promises to be the world's first full-feedback interactive percussive massager that provides a personalized recovery solution with muscle scanning technology. The Pact measures people's muscle tightness and provides personalized recovery guidance, creating an experience that adapts to them. An engineer at heart, Hunter-Jones got her first patent at age 16, and went on to MIT to get a degree in Mechanical Engineering. Her career began at SONOS, where she started in product development and then moved into project management. It wasn't until starting Impact Biosystems for Hunter-Jones to finally get the chance to combine her skills in engineering, product vision, and management with her passions for running, yoga, and overall health and wellness. Family is at the root of what drives Hunter-Jones. She gave birth to her son nine days before closing the company's latest round of funding (they've closed $6.5 million to date). On the podcast, we discuss Hunter-Jones' devotion to her family and her business, as well as her relationship with her father Ian Hunter, a PhD and the Hatsopoulos Professor of Mechanical Engineering at MIT. He also serves as Chief Inventor of Impact Biosystems. Hunter-Jones describes her father's lab at the barn of her childhood home as “Tony Stark's lab” where she and her father would work on inventions together throughout her childhood. The barn now serves as the headquarters for Impact Biosystems.

In this episode, Dr. Grant Stevens discusses the Ellacor™ micro-coring system with Karen Cronholm, President and CEO of Cytrellis Biosystems. Promising to improve more severe wrinkles, not just fine lines, this new FDA approved approach to non-surgical facial rejuvenation is designed to eliminate excess skin on the microscale. What's more, healing time for patients is typically faster than with energy-based devices, there's no scarring, and it promises to produce natural-looking results. Tune in to learn how this new technology is providing an alternative path for patients who want to look and feel younger on the latest episode of the Technology of Beauty.

In the Weeds Series 9 Episode 1: MSU Extension Environmental Management Educator Sarah Fronczak and Dr Steve Safferman, MSU Associate Professor in the Department of Biosystems & Agricultural Engineering, sit down with Sarah Hippensteel Hall,  Manager of Watershed Partnerships for the Miami Conservancy District, to discuss the interconnection of agriculture and storm water infrastructure  . 

In episode 65 of 17 Minutes of Science, we sat down with our very own Dr. Chris Hopkins. Chris is the Chief Scientific Officer here at InVivo Biosystems and is actively involved with customer projects and communications. Chris pioneered the commercialization of C. elegans transgenics at his previous company, Knudra, which he cofounded in 2009. In 2017, Chris joined the InVivo Biosystems team as CSO when Knudra was acquired by InVivo Biosystems (FKA NemaMetrix). As a scientist turned entrepreneur, he now pioneers the application of humanized animal models for discoveries in personalized medicine and natural products. Tune in to this episode to learn more from Chris about his career arc and hear his advice on how to make science your career one you are passionate about - whether it is academia, industry, or entrepreneurship.

Farm Talk Segment 1 - Leon Schumacher - NDSU Ag and Biosystems Department Chair

In the Weeds Series 8 Episode 5: MSU Extension Field Crops Educators Monica Jean and Sarah Fronczak sits down with Dr Steve Safferman, MSU Associate Professor in the Department of Biosystems & Agricultural Engineering,  to discuss adjusting nutrient management practices to prevent loss. 

This week, Marissa met with Alice Pack, USU alum and solutions engineer at Lucid. In their discussion, they touch on what it was like to graduate in spring of 2020 amidst the beginnings of the pandemic, how crucial networking was for Alice during her job search, and how the professional world differs from the academic world. On top of that, Alice dives into topics like the ins and outs of solutions engineering, finding "flow" in her work, how interpersonal skills have played a role in her technical job, and other careers of interest. Alice is a Solution Engineer at Lucid (Lucidchart + Lucidspark + Lucidchart Cloud Insights), a SaaS company with 12+ million users worldwide. Every day she connects with teams across the globe to help see and build the future using the Lucid Suite. She graduated from the Biological Engineering (BE) department at Utah State University. During that time she added a Computer Science minor, worked as a Public Speaking TA, and helped with the ABET accreditation process for the BE department.

Damien debates Ireland's methane targets with Myles Allen Professor of Geosystem at the University of Oxford , Dr Fionnuala Murphy, co-lead investigator on Farm Zero C and Assistant Professor at the School of Biosystems and Food Engineering in UCD and John Keane, President of Macra na Feirme.

Skye Edwards grew up in California's central valley, spending summers working on her family's ranch. When it came time for college, it was a hard decision to leave her tight knit community but her passion for learning took her to UC San Diego, The recent grad looks back on her time in college, how joining the Society of Hispanic Professional Engineers (SHPE) provided social and professional opportunities, and how she remained connected to her family while away at school. Series: "Education Channel" [Science] [Education] [Show ID: 37088]

Skye Edwards grew up in California's central valley, spending summers working on her family's ranch. When it came time for college, it was a hard decision to leave her tight knit community but her passion for learning took her to UC San Diego, The recent grad looks back on her time in college, how joining the Society of Hispanic Professional Engineers (SHPE) provided social and professional opportunities, and how she remained connected to her family while away at school. Series: "Education Channel" [Science] [Education] [Show ID: 37088]

Skye Edwards grew up in California's central valley, spending summers working on her family's ranch. When it came time for college, it was a hard decision to leave her tight knit community but her passion for learning took her to UC San Diego, The recent grad looks back on her time in college, how joining the Society of Hispanic Professional Engineers (SHPE) provided social and professional opportunities, and how she remained connected to her family while away at school. Series: "Education Channel" [Science] [Education] [Show ID: 37088]

Skye Edwards grew up in California's central valley, spending summers working on her family's ranch. When it came time for college, it was a hard decision to leave her tight knit community but her passion for learning took her to UC San Diego, The recent grad looks back on her time in college, how joining the Society of Hispanic Professional Engineers (SHPE) provided social and professional opportunities, and how she remained connected to her family while away at school. Series: "Education Channel" [Science] [Education] [Show ID: 37088]

Skye Edwards grew up in California's central valley, spending summers working on her family's ranch. When it came time for college, it was a hard decision to leave her tight knit community but her passion for learning took her to UC San Diego, The recent grad looks back on her time in college, how joining the Society of Hispanic Professional Engineers (SHPE) provided social and professional opportunities, and how she remained connected to her family while away at school. Series: "Education Channel" [Science] [Education] [Show ID: 37088]

Skye Edwards grew up in California's central valley, spending summers working on her family's ranch. When it came time for college, it was a hard decision to leave her tight knit community but her passion for learning took her to UC San Diego, The recent grad looks back on her time in college, how joining the Society of Hispanic Professional Engineers (SHPE) provided social and professional opportunities, and how she remained connected to her family while away at school. Series: "Education Channel" [Science] [Education] [Show ID: 37088]

Join us for episode 60 of 17 Minutes of Science as we talk with Dr. Adam Saunders, one of our own scientists at InVivo Biosystems. Dr. Saunders joins us to talk more about his work with our longevity services, his role in developing the Longevity platform, and why C. elegans make an ideal model for this area of research.

On this week's The Sci-Files, your hosts Chelsie and Danny interview Andrew Kearney. Andrew is a student in the MSU Department of Biosystems and Agricultural Engineering. Due to the low water activity (aw) and high osmotic pressure, sugar is generally recognized as a low microbiological risk source to human health. As a low moisture commodity sugar may receive little to no additional processing in a home environment.  Other low-moisture commodities, such as flour, were once also generally recognized as safe. However, following foodborne pathogen outbreaks in flour in recent years, there is interest in evaluating other low moisture commodities for foodborne pathogen risks. In response to outbreaks of pathogens in connection to flour, U.S. FDA guidance has suggested not to consume raw flour. This development has made assessing the risk of other shelf-stable commodities, like sugar, important to evaluate before a similar outbreak event occurs, despite no outbreaks of foodborne pathogens in added sugar within the U.S. having been reported to date. The objective of this study was to assess the survival of Salmonella in multiple sugar products during long-term storage. Granulated, powdered, brown, and liquid sugar obtained from commercial suppliers were inoculated with a 5-strain Salmonella cocktail via dry transfer. Samples were stored at three temperatures (4, 25, 37°C) in sealed containers, and sampled 12 times up to ~1,000 days.If you're interested in talking about your MSU research on the radio or nominating a student, please email Chelsie and Danny at scifiles@impact89fm.org. Check The Sci-Files out on Twitter, Facebook, Instagram, LinkedIn, and YouTube! 

LEXINGTON, Ky. (August 5, 2021) – The University of Kentucky Alumni Association started the Great Teacher Award program in 1961 to honor excellent teaching at the university. There have been 307 teachers honored since that first year. Nominations may only be submitted by current students. To receive the award, a candidate must: Hold the rank of full-time lecturer or above and have been a member of the faculty for the past three years at UK. Have superior knowledge of the subject matter. Have original and innovative classroom presentations. Demonstrate concern for students, both inside and outside the classroom setting. Not have been a recipient of the award for the past 10 years. A committee of the UK Alumni Association Board of Directors and a representative from the student organization Omicron Delta Kappa select the recipients based on objective rating and ranking of the eligible nominations submitted. This episode of Behind the Blue features part one of interviews with the 2021 winners of the Great Teacher Awards. Featured on this episode are: Clark Kebodeaux, representing the College of Pharmacy, Pharmacy Practice and Science Wayne Sanderson, representing both the College of Agriculture, Food and Environment, Department of Biosystems and Agricultural Engineering as well as the College of Public Health, Epidemiology Joseph H. Hammer, representing the College of Education, Department of Educational, School and Counseling Psychology. "Behind the Blue" is available on iTunes, Google Play, Stitcher and Spotify. Become a subscriber to receive new episodes of “Behind the Blue” each week. UK's latest medical breakthroughs, research, artists and writers will be featured, along with the most important news impacting the university. For questions or comments about this or any other episode of "Behind the Blue," email BehindTheBlue@uky.edu or tweet your question with #BehindTheBlue. Transcripts for this or other episodes of Behind the Blue can be downloaded from the show's blog page. To discover what's wildly possible at the University of Kentucky, click here.

The Fitness of Nature for Mankind featuring Biologist Michael Denton Watch this presentation at- https://youtu.be/9SL_xqSvWqU 36,385 views Discovery Science 123K subscribers Renowned author and biologist Michael Denton gives a new expression to what he calls the “medieval synthesis” of knowledge about life, now enjoying a “Reconquista” thanks to modern science. In charming and lyrical yet rigorous fashion, Denton reviews the intelligent design evidence detailed in his books, including the most recent, The Miracle of the Cell. Join him as he explores the myriad of ways nature is fit not just for life, but for human life. Denton is author of the new book "The Miracle of the Cell" (2020) as well as many other books such as "Nature's Destiny," "Fire-Maker," "The Wonder of Water," and "Evolution: Still a Theory in Crisis." You will never think of nature in the same way after you watch this presentation! Dr. Denton's new book The Miracle of the Cell [https://www.discovery.org/store/produ...] provides compelling evidence that long before life emerged on our planet, the design of the carbon-based cell was foreshadowed in the order of nature, in the exquisite fitness of the laws of nature for this foundational unit of all life on Earth. Nowhere is this fitness more apparent than in the properties of the key atomic constituents of the cell. Each of the atoms of life — including carbon, hydrogen, oxygen, and nitrogen, as well as several metal elements — features a suite of unique properties fine-tuned to serve highly specific, indispensable roles in the cell. Moreover, some of these properties are specifically fit for essential roles in the cells of advanced aerobic organisms like ourselves. Author Michael Denton is a Senior Fellow with Discovery Institute's Center for Science and Culture. He holds an MD from Bristol University and a PhD in biochemistry from King's College in London. His previous books include Evolution: A Theory in Crisis and Nature's Destiny: How the Laws of Biology Reveal Purpose in the Universe. He has published his work in Nature, Nature Genetics, BioSystems, Human Genetics, and Biology and Philosophy. Be sure to check out these related videos: Marcos Eberlin: Earth as the “Presidential Suite” of the Universe https://youtu.be/dFrOWEWHWZg Water, Ultimate Giver of Life, Points to Intelligent Design https://youtu.be/e2i0g1sL-X4 Conversations with William Dembski–Information All the Way Down https://youtu.be/BnVss3QseCw ============================ The Discovery Science News Channel is the official Youtube channel of Discovery Institute's Center for Science & Culture. The CSC is the institutional hub for scientists, educators, and inquiring minds who think that nature supplies compelling evidence of intelligent design. The CSC supports research, sponsors educational programs, defends free speech, and produce articles, books, and multimedia content. For more information visit https://www.discovery.org/id/ http://www.evolutionnews.org/ http://www.intelligentdesign.org/ Follow us on Facebook and Twitter: Twitter: @discoverycsc Facebook: https://www.facebook.com/discoverycsc/ Visit other Youtube channels connected to the Center for Science & Culture Discovery Institute: https://www.youtube.com/user/Discover... Dr. Stephen C. Meyer: https://www.youtube.com/user/DrStephe... The Magician's Twin - CS Lewis & Evolution: https://www.youtube.com/user/cslewisweb Darwin's Heretic - Alfred Russel Wallce: https://www.youtube.com/user/AlfredRW... HELP ACU SPREAD THE WORD!   Ways to subscribe to the American Conservative University Podcast Click here to subscribe via Apple Podcasts Click here to subscribe via RSS You can also subscribe via Stitcher FM Player Podcast Addict Tune-in Podcasts Pandora Look us up on Amazon Prime   If you like this episode head on over to Apple Podcasts and kindly leave us a rating, a review and subscribe! People find us through our good reviews.   FEEDBACK- You can ask your questions, make comments, submit ideas for shows and lots more. Let your voice be heard. Email us at americanconservativeuniversity@americanconservativeuniversity.com     Help CSI Stamp Out Slavery In Sudan Join us in our effort to free over 350 slaves. Listeners to the Eric Metaxas Show will remember our annual effort to free Christians who have been enslaved for simply acknowledging Jesus Christ as their Savior. As we celebrate the birth of Christ this Christmas, join us in giving new life to brothers and sisters in Sudan who have enslaved as a result of their faith. https://csi-usa.org/metaxas   https://csi-usa.org/slavery/   Typical Aid for the Enslaved A ration of sorghum, a local nutrient-rich staple food A dairy goat A “Sack of Hope,” a survival kit containing essential items such as tarp for shelter, a cooking pan, a water canister, a mosquito net, a blanket, a handheld sickle, and fishing hooks. Release celebrations include prayer and gathering for a meal, and medical care for those in need. The CSI team provides comfort, encouragement, and a shoulder to lean on while they tell their stories and begin their new lives. Thank you for your compassion  Giving the Gift of Freedom and Hope to the Enslaved South Sudanese

The Fitness of Nature for Mankind featuring Biologist Michael Denton Watch this presentation at- https://youtu.be/9SL_xqSvWqU 36,385 views Discovery Science 123K subscribers Renowned author and biologist Michael Denton gives a new expression to what he calls the “medieval synthesis” of knowledge about life, now enjoying a “Reconquista” thanks to modern science. In charming and lyrical yet rigorous fashion, Denton reviews the intelligent design evidence detailed in his books, including the most recent, The Miracle of the Cell. Join him as he explores the myriad of ways nature is fit not just for life, but for human life. Denton is author of the new book "The Miracle of the Cell" (2020) as well as many other books such as "Nature's Destiny," "Fire-Maker," "The Wonder of Water," and "Evolution: Still a Theory in Crisis." You will never think of nature in the same way after you watch this presentation! Dr. Denton's new book The Miracle of the Cell [https://www.discovery.org/store/produ...] provides compelling evidence that long before life emerged on our planet, the design of the carbon-based cell was foreshadowed in the order of nature, in the exquisite fitness of the laws of nature for this foundational unit of all life on Earth. Nowhere is this fitness more apparent than in the properties of the key atomic constituents of the cell. Each of the atoms of life — including carbon, hydrogen, oxygen, and nitrogen, as well as several metal elements — features a suite of unique properties fine-tuned to serve highly specific, indispensable roles in the cell. Moreover, some of these properties are specifically fit for essential roles in the cells of advanced aerobic organisms like ourselves. Author Michael Denton is a Senior Fellow with Discovery Institute's Center for Science and Culture. He holds an MD from Bristol University and a PhD in biochemistry from King's College in London. His previous books include Evolution: A Theory in Crisis and Nature's Destiny: How the Laws of Biology Reveal Purpose in the Universe. He has published his work in Nature, Nature Genetics, BioSystems, Human Genetics, and Biology and Philosophy. Be sure to check out these related videos: Marcos Eberlin: Earth as the “Presidential Suite” of the Universe https://youtu.be/dFrOWEWHWZg Water, Ultimate Giver of Life, Points to Intelligent Design https://youtu.be/e2i0g1sL-X4 Conversations with William Dembski–Information All the Way Down https://youtu.be/BnVss3QseCw ============================ The Discovery Science News Channel is the official Youtube channel of Discovery Institute's Center for Science & Culture. The CSC is the institutional hub for scientists, educators, and inquiring minds who think that nature supplies compelling evidence of intelligent design. The CSC supports research, sponsors educational programs, defends free speech, and produce articles, books, and multimedia content. For more information visit https://www.discovery.org/id/ http://www.evolutionnews.org/ http://www.intelligentdesign.org/ Follow us on Facebook and Twitter: Twitter: @discoverycsc Facebook: https://www.facebook.com/discoverycsc/ Visit other Youtube channels connected to the Center for Science & Culture Discovery Institute: https://www.youtube.com/user/Discover... Dr. Stephen C. Meyer: https://www.youtube.com/user/DrStephe... The Magician's Twin - CS Lewis & Evolution: https://www.youtube.com/user/cslewisweb Darwin's Heretic - Alfred Russel Wallce: https://www.youtube.com/user/AlfredRW... HELP ACU SPREAD THE WORD!   Ways to subscribe to the American Conservative University Podcast Click here to subscribe via Apple Podcasts Click here to subscribe via RSS You can also subscribe via Stitcher FM Player Podcast Addict Tune-in Podcasts Pandora Look us up on Amazon Prime   If you like this episode head on over to Apple Podcasts and kindly leave us a rating, a review and subscribe! People find us through our good reviews.   FEEDBACK- You can ask your questions, make comments, submit ideas for shows and lots more. Let your voice be heard. Email us at americanconservativeuniversity@americanconservativeuniversity.com     Help CSI Stamp Out Slavery In Sudan Join us in our effort to free over 350 slaves. Listeners to the Eric Metaxas Show will remember our annual effort to free Christians who have been enslaved for simply acknowledging Jesus Christ as their Savior. As we celebrate the birth of Christ this Christmas, join us in giving new life to brothers and sisters in Sudan who have enslaved as a result of their faith. https://csi-usa.org/metaxas   https://csi-usa.org/slavery/   Typical Aid for the Enslaved A ration of sorghum, a local nutrient-rich staple food A dairy goat A “Sack of Hope,” a survival kit containing essential items such as tarp for shelter, a cooking pan, a water canister, a mosquito net, a blanket, a handheld sickle, and fishing hooks. Release celebrations include prayer and gathering for a meal, and medical care for those in need. The CSI team provides comfort, encouragement, and a shoulder to lean on while they tell their stories and begin their new lives. Thank you for your compassion  Giving the Gift of Freedom and Hope to the Enslaved South Sudanese

TARA Biosystems has raised $21.3 million to date and is the world's only company that generates human cardiac tissue—outside of the human body. Instead of testing on animals, researchers will be able to test drugs right on actual human tissue and the industry will be able to save time, money and unnecessary animal suffering throughout the drug development process. In this episode, we feature an eye-opening interview with TARA Biosystems' CEO Misti Ushio, to learn more about how their breakthrough technology came to be, how it works, the enormous potential it holds, as well as some of the challenges that still need to be overcome for it and other similar technologies to be used widely in the “real world.” In the episode intro, Sharanya and Ulara share some key stats and figures from the animal testing alternatives landscape, and discuss some of the surprisingly major players already involved in the emerging space, including government leaders and regulatory agencies.  TARA Biosystems' website: https://tarabiosystems.com/ The article we refer to in the episode is “The next phase of drug creation: Why animal models are on the brink of extinction” via Pharma Manufacturing: https://www.pharmamanufacturing.com/articles/2021/the-next-phase-of-drug-creation/ Support the show (https://www.afteranimals.com/support-us)

From her TED talks and her appearances on PBS, geneticist Wendy Chung is known to millions of people as an expert on autism. But thanks to funding from the Simons Foundation, she's also known to tens of thousands of people with autism and their families as the leader of history's largest study of the genetics of autism spectrum disorder (ASD). It's called SPARK, for Simons Foundation Powering Autism Research for Knowledge, and it's a big-data exercise of unprecedented proportions.SPARK is partnering with more than 30 medical schools and research centers to recruit 50,000 families with members affected the ASD. Participants have their DNA sequenced, enabling SPARK to build a list of genetic differences linked to autism as a starting point for research on the causes and mechanisms behind the condition. At the moment the list includes 157 single genes and 28 copy number variants. But changes in these known ASD genes show up in only about 10 percent of families studied—suggesting that the existing list is just the tip of the iceberg. Identifying common gene variants with small effects requires large sample sizes, which is why SPARK aims to recruit so many participants. At 50,000, the SPARK researchers think they'll be able to find as many as 150 individuals with mutations in each of the 100 most common ASD genes.SPARK is unusual not just for its scale but for its participant-friendly design. Biospecimens such as saliva samples are mailed in, and patient data is collected through remote online questionnaires rather than in a clinic. The study also follows participants longitudinally, and it returns genetic data to them—an uncommon practice in large studies due to its resource-intensiveness.Chun trained in biochemistry and economics at Cornell, earned a PhD in genetics from Rockefeller University, and got her MD from Cornell University Medical College. On top of her role as SPARK's principal investigator, she is also the  Kennedy Family Professor of Pediatrics and Medicine and Chief of Clinical Genetics at Columbia University Medical Center.  Please rate and review MoneyBall Medicine on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:• Launch the “Podcasts” app on your device. If you can't find this app, swipe all the way to the left on your home screen until you're on the Search page. Tap the search field at the top and type in “Podcasts.” Apple's Podcasts app should show up in the search results.• Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner.• Type MoneyBall Medicine into the search field and press the Search button.• In the search results, click on the MoneyBall Medicine logo.• On the next page, scroll down until you see the Ratings & Reviews section. Below that, you'll see five purple stars.• Tap the stars to rate the show.• Scroll down a little farther. You'll see a purple link saying “Write a Review.”• On the next screen, you'll see the stars again. You can tap them to leave a rating if you haven't already.• In the Title field, type a summary for your review.• In the Review field, type your review.• When you're finished, click Send.• That's it, you're done. Thanks!Full TranscriptHarry Glorikian: I'm Harry Glorikian, and this is MoneyBall Medicine, the interview podcast where we meet researchers, entrepreneurs, and physicians who are using the power of data to improve patient health and make healthcare delivery more efficient. You can think of each episode as a new chapter in the never-ending audio version of my 2017 book, “MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market.” If you like the show, please do us a favor and leave a rating and review at Apple Podcasts.Harry Glorikian: From her TED talks and her appearances on PBS, geneticist Wendy Chung is known to millions of people as an expert on autism. But thanks to funding from the Simons Foundation, she's also known to tens of thousands of people with autism and their families as the leader of history's largest study of the genetics of autism spectrum disorder.It's called SPARK, which stands for Simons Foundation Powering Autism Research for Knowledge. The study has enrolled over 100,000 individuals with autism and another 165,000 family members. It's designed not just to advance understanding of autism's causes but to follow people over years or decades and help them lead successful lives.Chung calls it the Framingham of autism, a reference to the famous Framingham heart study that began in 1948 and is still going on today. So, talk about big data! When you're sequencing the exomes, that is, the expressed genes, of a quarter million people, and sharing all of your data back with patients, you're dealing with an unprecedented data management challenge. In fact, SPARK has so much data Chung jokes that she has to compete with Bitcoin farmers to buy new computer servers.But Chung isn't finished. She wants to keep going until SPARK has enrolled 50,000 families altogether. The hope is that with that volume of genetic data, scientists will be able to to figure out which genetic variants that contribute to autism might be amenable to treatment with new drugs molecules. And because the SPARK study is also collecting data about the lives of people with autism as they grow up and encounter all of life's challenges, Chung hopes the project will be able to provide individuals on the ASD spectrum with coaching and other forms of support.A few weeks back Wendy made time to talk with me about all that. And now here's our conversation.Harry Glorikian: Dr. Chung, welcome to the show. Wendy Chung: Thank you for having me today. Harry Glorikian: So I feel like I almost know you from watching you on PBS and watching you interact with your patients. So you'll forgive me if I'm more comfortable than, than actually meeting you for the first time face to face.Or I should say virtually, I think we've been doing this too long now. But, you know, I know we're going to talk a lot about your program SPARK today. But I'd like to sort of start with a little bit of maybe of history and some background, you know, it seems like one big question that attracts you above all.Others is the genetic basis of human disease. And so how did you first get interested in that?Wendy Chung: All right, so I'll go way, way back. I think I've always known that I wanted to go into science and medicine and tried to figure out a way to put things together. And for me, I guess the moment, and you'll be able to calculate my age from this.But the year that I started, my MD-PhD training program was the year the announcement was made that we would start the human genome project. And I knew I already had a passion. For what we call inborn errors of metabolism or metabolic diseases, but it became very clear to me that we would have insight into the genes and the genome to treat conditions like that.Plus other ones as well. And an MD-PhD program takes a long time to finish your entire training going to graduate school and medical school and residency and fellowship and all of those things. And so you could project out. that it might be as long as 15 years before I would finish my training.And if you looked at the projections for how long it would take to finish the genome, they basically converged about the same time. And I'm one of these people. I like to think that I'm a strategic planner and visionary. I don't want to sound egotistical on this, but I am a planner. And as I started planning, I thought to myself, well, this is really going to be incredible.The power that we'll have as a scientific and medical community. And this whole job description doesn't exist. You know, so we are gonna need people to be essentially, genomicist a brand new field of both science and medicine. And I kinda like puzzles. I like logic and I like having definitive answers.And that's what I think the genetics often provides us. And so it's really with the excitement of the opportunities with a brand new field along with just. The way my mind works, that this was really perfect. And, and I was lucky. I have to admit to be able to discover that early in my career. So what I start out to do almost the first day of medical school has really been what I've continued to do for my entire career.So, anyway, Harry Glorikian: well that is that's, that's incredibly lucky. I mean, I do believe in a process and a plan. I can't say that at a young age, like you, I knew exactly what I was going to do when I grew up. It seems to be in the same area of, of. Biology, but I think that's the only common theme that I would say. So this program SPARK grew out of the existing Simmons foundation called SAFARI right?The Simmons foundation, autism research initiative. You were on the board of SAFARI for a long time. And then, and then you became a program director of clinical research. Can you talk about. Why you felt drawn deeper and deeper into specifically autism research? Wendy Chung: Sure. So I'm trained as a pediatrician and a medical geneticist and a fair number of the patients that I see.And this was true for pre-existing before SAFARI or SPARK ever came along. But a lot of my patients have neurodevelopmental conditions and or autism. So it's a common reason for people coming to see us over my career. A lot has changed in terms of our ability to understand the underlying etiology, especially with the genetic etiology.And I will give credit that was in large part due to the SAFARI program at the Simons foundation, they really did have this original vision in terms of, we needed to understand the brain and behavior across for individuals across the spectrum. And that a really. Powerful tool to do that would be genetics.It's not all genetics. I want to be clear about that. And it's a wide spectrum. But I got pulled in just because of my expertise as a geneticists to advise the SAFARI program. And as you said it started out as advice and due to. Individuals who were there and got to know me and thought I might be able to contribute.in even bigger ways got sort of pulled from the outside to the inside, so to speak. And as that happened and understanding what the gaps were SPARK or Simons Foundation powering autism research for knowledge is the acronym. That was a vision realizing that to really make the. It's scientific inroads, we needed to do.We needed to think big. And that's because autism is not one condition. It's quite heterogeneous. It's quite complicated in terms of etiologies. And we really need to base, we need to have hard foundations, really solid evidence to be able to know what direction to go with the science and that genetics provides that solid foundation.Harry Glorikian: Yeah. I'd say it's, you know, I've I was trying to get ready for this. And I was trying to do as much reading as I could. And I realized like, We know, we know some things, but there's a lot we don't know. And then there's certain things that seem to trigger it and we're not, we don't fully understand what all those things.It's a very interesting sort of set of reading that I went through very quickly. So I'm probably like a millimeter deep and pretty wide compared to you. But it is interesting how. Genomics and genetics have, are really driving a lot of areas that we see right now. It's funny because I remember when someone way back in the beginning, so I'm dating myself also.It was said, why would you sequence anything? And now it's like, we, we want to sequence everything. And the information that it's giving us. So can you give us a high level explanation of what SPARK is and. How different it is from some of the previous studies of autism spectrum disorder and in terms of scale and goals.And, and when did you decide and how did you decide to embark on this? Cause it's I was reading this study. I mean, it is, it's a pretty ambitious goal. Wendy Chung: So again, At the Simons Foundation we had started out with something called the Simon simplex collection. And I think of that as sort of the first foray into the genomics, that was to give you a sense of order of magnitude about 2,500 individuals with autism.So, you know, a big, big order, you know, 20 fold difference in terms of the original goals, at least for SPARK But that was, I think of as being very careful in terms of making sure the individuals within that Simon simplex collection, they went through very extensive in-person evaluations with masterful clinicians, psychologists to make sure the diagnosis was unambiguous and then had the genomics sort of layered on top of that.And I won't get into the specifics of cost per person to run through that, but that was really, I think, of as the platinum version. And that was important for the field. To be able to have that again as a solid foundation and to be able to make some statistical arguments about what sample size did you need to be able to get to understand the entire complexity of autism.So it was definitely foundational and necessary. But in terms of being able to do that with about 2,500 individuals, you could make estimates, right? But in terms of the number of genes that would be involved in autism, it would be around the order of 500. And so that's just for, you know, a certain portion of the spectrum as well.And you can understand therefore, the complexity in terms of what we're talking about. And, and I'm just because I know there are some people who may not understand exactly what I'm talking about. Let me just be a little bit more granular. For people who come in to see me with a child with autism example, I'll have some individuals who may be non-verbal.They, they will never be verbal. That is they'll never talk. They may be able to communicate in some way, but they may be intellectually disabled. They may have. Seizures or epilepsy. They may have even medical problems associated with that. And that's one portion of the spectrum to another portion of the spectrum are individuals who are just incredible in that their mind works differently.It doesn't necessarily work in a wrong way. It just works differently. And they see the world in a different way. And oftentimes I have to say are profoundly insightful in terms of. Problem solving because they do come at it from a different direction and they do have just fresh eyes to be able to look at complex problems.So, and again, I, I want to be very clear in terms of how I'm talking about this. I don't consider autism a disease in that way. It's a difference, right. In terms of all of what we're talking about. And I want to be very clear also in terms of the genetics. Yeah. That this is not to get rid of anyone. This is not to be able to have a eugenics movement where we're trying to eliminate individuals with autism.It has nothing at all to do with that. It really has to do with understanding the underlying biology of how the brain works, because we've really been so much in the dark that people had theories and hypotheses, and they'd waste a lot of energy doing the wrong science because it wasn't based on that foundation of really.Truth with a capital T what are the molecules in the brain? What are the different parts of the brain that are involved? How does it change over time? We really needed that foundational information to go from kind of the dark ages of autism research into the modern age and era. And so in doing so that's the Simon simplex collection found, you know, allowed us to see what sample size did we need.So we started doing some rigorous statistical calculations of how many we'd need to get to that goal of having maybe not every single gene, but the majority of genes. And that's where the calculation of having 50,000 families. originally came up. And so that was our original goal to be able to scale that you know, 20 fold higher than what we'd done with Simon simplex collection.But if you started looking at number one who was able to participate, like who literally could give up a couple of days of their life to go in for these evaluations who was close enough to one of these study centers to do it it, it was. Partially an equity issue for me that I wanted to make sure everyone could get access to be part of understanding better and to be represented, because if you're not represented, your voice may not be heard in terms of the research.So part of it was from that point of view is from a convenience point of view making sure that individuals wherever in the United States, if they wanted to be in their pajamas at 11 o'clock at night, to be able to do this, they could do it. Then, and it wasn't so burdensome. So the whole process, you know, it takes maybe an hour or so to be able to register and become part of this, not to say that you can't do more than that first hour, but to start this off, it becomes easier.So it was with that and, you know, we've had, in terms of timing, we've had lots of ability to do things online that we couldn't do before. So when we first started this, you know, the internet wasn't as evolved as it is, and there's just a lot more we can do from home. And in general, one of the parts about SPARK that I think is really important is.That it's meant to capture people where they are. And so, I mean that both in terms of just the convenience of participating, I also mean in terms of behaviors. And so, again, as a clinician, I have children with autism who come into my office, who I have to admit it's a terrible experience for them. They're petrified in terms of, you know, they like it.They liked to understand what's coming. They don't like surprises. They get anxious. Being out of their elements is really hard for them. And so being able to do things where they're on their home turf, they're on their home territory and being able to capture behaviors where they really are rather than our artificial environments of being at a laboratory at a university at a hospital.All I think is really important to truly see what life is like for individuals. So we're trying to do all of those things in terms of really capturing, you know, more of accurate information, more data. So in terms of doing this, not just the one time you can come in and be evaluated, but over your life course.And so that's one of the things about SPARK is this is not a one and done type of. Snapshot of who you are. This is really thinking about a life course. And I really, I want to emphasize this. One of the other things about SPARK is not just the number of individuals, but it's the longevity of what we're planning to do.We've, we're celebrating our fifth anniversary this year. And from my point of view, we're planning on going this for a lot, lot longer. I don't know if it's going to be 50 years. I don't know if I'll last for myself for 50 years. But but, but this is, I tell people who will understand what I mean, this is meant to be kind of like the Framingham of autism.Another words, you know, being able to really see people through different changes over their life course, different stages of life, different challenges, trajectories of how things evolve and importantly, what we can do to change that trajectory potentially or support people better. So that sometimes when people fall through the cracks with young adults, especially is one area that I'm mindful of.How do we prop them up? How do we make sure that transition is easier? And so, like I said, for anyone, wherever they are on the spectrum, I think there's always some time, some place in your life where you need an extra helping hand. And so I hope this will start to provide that evidence base for where we can provide that helping hand and have the greatest potential impact.Harry Glorikian: Yeah, no, it's, it's this term we're using autism is, is, is quite captures a very broad set of. People as, as you indicated, like, you know, you know, Elon Musk recently got up on SNL. Right. And you had to know that he was a little off anyway before that, but, you know, I actually believe that people like that can see the world in a certain light, through a certain lens that a lot of other people would be like, I have no idea what you're talking about.I can't see it. So. All of these people, right on one spectrum or the other, which I think all of them add value as, as they're going through their lives. But the other interesting part of this study is you guys are sharing the results with participants, right. Which is not usual and not, I don't think trivial to do.So. You've got a unprecedented level of engagement and data returned to individuals and their families. You're not just returning genetic data, but aggregate reports, which in accessible language, which, you know, I'm trying to re I just finished my third book, trying to write it more accessible, of our world and I can tell you that was truly challenging.So I, what was the philosophy behind that? And what are your challenges around trying to do that?Wendy Chung: Right. So you're, you're absolutely right. I, I think in a very good way, we've been from the very beginning, and even in the planning stages of this had participants as part of that planning process and they still are literally on our staff on everything that we do, they are integrated on our teams.So let me paint a picture for you. About some of the details of what you're talking about. So as of this morning, as an example, we have over a hundred thousand individuals with autism in SPARK. We have over 265,000 total participants. So the reason why the difference for those is some of those are.Parents for instance of individuals with autism or siblings because we do encourage families to participate. So you can see that this is massive, right? This is over a quarter of a million people that we're trying to be able to in some way, juggle with all of this. And so for me, that was, you know, I don't unlike.Most of my other research studies. I don't personally know every single person in the study. I never will, unfortunately, but we do have anchors of 31 clinical sites around the country. So that's one of the things that we do to make sure that we have our finger on the pulse in some way of our participants.But I will also admit you could just be, like I said, in your jammies at 11 o'clock at night tonight and Google SPARK for autism and be able to find and sign up for this, you know, there's no, you don't have to be at one of these sites to do this. You're right. That the philosophy I heard from our participants from the very beginning, and some people may have heard this term is nothing about us without us.And so in terms of research, the idea that we want to be as research participants, we want to be part of the research team. We want to be able to have a voice we want to help you do your job better as researchers. So, you know, it's not just in a selfish way. It's about, what's going to really make us committed to doing this, not as a one and done study, but as the picture I painted to be able to continue to participate for decades forward. And so in hearing that then in hearing what was important to participants, keeping in mind that I can't do everything for everyone, you know, we have to have compromises in this. It became important for people to have access to their genetic information.But not just like, give me a flash drive with my raw data. Right. That's not helpful. If you're interpreting this information to understand genetic causes of autism and you find that for me, let me know about that. And in addition, and I, I am proud of the way we did this. We did this, not with just sort of sending someone, an email and sending, okay, well, guess what, you've got to SHANK3 variant, and this is the cause of your autism.We do this. And I think about this for myself, what would I want to do for me? What would I want to do for my family? If this were my son, how would I want this done? If I weren't a geneticist? And so we've built in I call it, choose your own adventure, but we give people choice in the sense that. When we return, number one, it costs no one, anything.Let me be very clear about that. So it's not like you're buying a test or anything. If anything, we will not. If anything, we do give you a token of a gift certificate to thank you for your time, because we know it takes time to be able to do this, but we pay for everything with this. And so we do it.For those that are aficionados. We do a process called exome sequencing to be able to look at comprehensively across the genome as we do this. And it's about right now as of today, about 10% of our participants, where we find something that we can be pretty certain is the cause of the autism in the family.And we. Again, pay for this ourselves to have a second group of people. Double check, make sure it's correct. And then the choose your own adventure is either you can choose to have your own doctor to give you that information back and explain it to you. Or if you don't feel like your doctor is the best person to do it, because maybe they're not a geneticist, maybe they don't have any idea what we're talking about.We pay for the study centrally to have a trained set of genetic counselors, be able to return the information. And I, and my team have personally written out what we call brochures in. As you were talking about lay person language that describe each one of the over a hundred conditions that we now return.And so it was a lot of work to write each one of those brochures for each one of those conditions. And to keep them up to date, but. That's how committed we are to this community. That's how important I think it is. Harry Glorikian: I, I almost feel like I need to sit down. That's just the enormity of that task is, is is extremely commendable.I can't believe I'm getting a commercial enterprise like to do that. Right. Is, is not trivial. So. That's that's incredible. Wendy Chung: This is like the Ginsu knife set, but wait, there's more! So we also appreciate that not everyone is going to have a genetic result. And so we also have parents for instance, that are completing questionnaires that tell us about how their child is doing in terms of behaviors or you know, things that are related to autism or behavioral issues.And I have to say during COVID as well, Especially, this was a big issue for many people, not just individuals with autism but about psychological differences and making adjustments during COVID. So within that we give and these are again, standard psychometric tests that are used so-called in the industry.So in other words, by psychologists who are practicing we give that information back to families. We use infographics. And so all of this has been test driven in plain language with groups of individuals that are average parents, individuals with autism. We have a commendable group of about 80 of our participants that sit on our board again, giving us feedback before we go live with any of this, telling us how to tweak it, to make this more accessible, using different infographics, to be able to make this easy.But every one of those things that we can return, then. We return it to our participants. We have something called a research match program. So we have over 150 researchers who use SPARK as a way of letting the community know about the research they're doing and being able to match SPARK participants with research so that this is, as you can see, it continues to kind of organically grow, not just SPARK, but the entire research community.And a requirement for every one of those researchers is that when they complete their research, they have to actually give that information back to the people who participated in the research, into the SPARK community, in lay language. So in a way that families and individuals. Can access and understand it.And we have many of them give webinars or be featured in our newsletter, but the whole process is we're learning together. And I want, I want people to see how science is done. I want them to be part of like the front lines. Like they're getting the preview in terms of hot off the presses information.So with this, hopefully this is a movement in science. It's not just SPARK. I hope all, all people do this. Harry Glorikian: I was going to say, I think you need to teach a master class on how to do this because. I'm not familiar. Maybe somebody else is doing it, but I'm not familiar with it. Usually I get gobbledygook back.I mean, I just actually volunteered to do a diagnostic clinical trial and it was, and I'm in the, in the business and I was reading what they wanted and I was like, I don't understand this at all. I don't understand what you want from me. I don't understand what I'm going to get back. I don't understand anything.I'm not participating. I don't have time for this. So but all the stuff you said now really rings in my head of A), a data management challenge, B), analytics challenge, and C), how do you automate some of this? Because the first thing that goes into my head is is there, you know, some aspect of AI or machine learning that can do some of this because.If I'm not mistaken, every time you discover more variants, you're going back and reanalyzing the genomic data. And that becomes exponentially a bigger and bigger task. If there isn't some level of automation to sort of make part of that more turnkey. So what are you doing there? Wendy Chung: Yep. So you're absolutely right about you know, we have thought about ways to scale.This scale is one of my favorite words right now. Because you're right, that each time we get more people that come in and more data, we turn, we, you know, turn the crank. One more time. Knowledge is increasing around us about the brain and behavior. We're adding that and putting that back in, and then again, increasing the robustness of what we do.And we do want to be really rigorous in terms of as we're doing this. So that's on the genetic side. And so there are. Our ways of being able to do that, I will say it takes more and more in terms of computing time or sort of, you know, person power to do this Bitcoin, by the way has been a problem.They're buying a lot of servers. They need to, you know, free up some of those for science anyway. But aside from that there's also the issue in terms of people report to us behaviors and in an interesting way. And it's just kind of what happens when you do science this way. Not everyone is perfect in terms of how they.Decide to participate and I get that. And so what I mean by that is there's missing ness of data that we as researchers have, you know, we realized that we've used the machine learning and some ways to fill in those missing pieces. And so what we've tried to do is use machine learning. I talked about a spectrum for instance, and people are at different ends of the spectrum that ends up being incredibly important to interpret the genomic information, as well as information about other people in the family.And yeah. How their genetics go with their own particular place on the spectrum. And so putting all that together, we can get a profile with machine learning, to fill in some of the gaps, fill in some of the blanks, understand issues with trajectory, and then combine that with the genetics. And so the good thing, and this is another reason why we set up SPARK the way it is.I'll be very clear to anyone who's thinking about this, either as a contributor, as a user. Everything is de-identified of course. So no one knows who any participant is, but I, I set this up originally so that the broad research community would be able to think about these problems. And I tried to de-risk it for any scientists who wanted to enter this.So as a data scientist, for instance, You may not be an expert in autism, but I want you to be able to contribute in terms of doing this. And so the way this is set up again is the entry to access this as you do. We make sure you're a real bonafide researcher. We do go through a rigorous check of that, but you don't have to be an autism researcher.You could be in industry, you could be an academia, you know, you could be at a private foundation. We just want to make sure you're doing good science. And I have been saying that many of the people who are using the data. are not necessarily, they didn't start out as autism researchers. They simply are data scientists, computational biologists, who are able to look at the data in interesting ways.And I think the more we can bring smart people to the table on this, the faster we'll get some of the answers we need. [musical transition]Harry Glorikian: I want to pause the conversation for a minute to make a quick request. If you're a fan of MoneyBall Medicine, you know that we've published dozens of interviews with leading scientists and entrepreneurs exploring the boundaries of data-driven healthcare and research. And you can listen to all of those episodes for free at Apple Podcasts, or at my website glorikian.com, or wherever you get your podcasts.There's one small thing you can do in return, and that's to leave a rating and a review of the show on Apple Podcasts. It's one of the best ways to help other listeners find and follow the show.If you've never posted a review or a rating, it's easy. All you have to do is open the Apple Podcasts app on your smartphone, search for MoneyBall Medicine, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but it'll help us out immensely. Thank you! And now back to the show.[musical transition]Harry Glorikian: Did you ever think when you were getting your MD-PhD that you'd have to become a data scientist or an IT manager? Wendy Chung: So not exactly. And in fact, so anyway, I'll tell you sort of how I grew up. I was actually as growing up, if you had asked me what my natural proclivity or skill was, I was definitely mathematically inclined.It was very data science inclined, very mathematically inclined. And. Probably even too good in some ways for my own shoes. Cause I kind of got ahead of myself in terms of taking very advanced courses at an early age it was, I'll never forget this conversation though. I had a discussion with my math professor as an undergraduate and said, you know, I'm really good at this stuff, but what can I do with a degree in math?And he said, oh, well you can go work at an insurance company. You can be an actuary. You can. You can figure out what rates, you know, people should be paying in terms of their insurance. And I said, Really that's what you do with a math degree. And like, literally I did a 180 pivot and said, that's not worth, you know, going into for that.And that was, I have to admit unfortunate and, and, you know, I, I'm not saying everything happens for a reason. I have no regrets in terms of what I've done with my life. I think that, you know, I found my home and, you know, a great thing to do. But I do have some regrets that, you know, He had that influence on me in that way.So, you know, I could've seen myself the time when I grew up, you know, we were just starting to have personal computers, you know, we were, we didn't even have emails or internet or, you know, it's a completely different world than when I was training. So I will admit. That a lot of what I do is done by others.I think that's a good thing. I will say team science is incredibly important. And even though I'm here talking to you today, really I'm representing literally hundreds of scientists behind the teams that are actually doing the hard work, whether it's coding, to be able to make our interfaces for users valuable, whether it's data scientists analyzing the data, psychologists neurobiologists, you know, there are just amazing people that are behind the scenes doing all of this.And so when it comes to a lot of the really heavy lifting. I will admit that they're the ones doing the heavy lifting and, you know, in a good way, I think I've got the vision to guide the ship. But there are a lot of really smart, especially young minds that are driving a lot of the science. Harry Glorikian: So I want to switch here and switch to recruitment here just for a minute or so, because I also want to ask some of the listeners to point people in, in the direction of this study.Right. Dump more people the better, but W w where are you now from a numbers perspective? The last numbers that I saw were. 18,000 individuals in 2017 and 28,000 family members on top of that, I'm sure it's grown since then, but w what are the numbers right now? Wendy Chung: Yep. So, as I was saying, you know, the numbers are in terms of people registered just over a hundred thousand with autism and just over, it's about 265,000 total.So I'm not gonna. Anyway, I'll I'll go ahead and just say it. So there are individuals who get stuck at various different stages in the process. I will say, dads seem to get stuck more than moms do, and I can understand dads are busy. But when I, some of the numbers you were quoting, for instance, we have registration.We also have send out a saliva kit for people to be able to donate a DNA sample. So they spit in a tube and they send that back. And so we have a fair number of people that get stuck at that point and dads in particular. Yeah. When we started out the sequencing, one of the things that I'll just give a little science behind this is that we call them Denovo genetic variants.So variants that are brand new in the individual with autism are oftentimes some of that 10% that we'll recognize as a cause of autism. I'm not saying those are the only causes, but those are the ones we recognize at this point. So it became a, and has always been really critical to have both mother and father and the individual with autism whenever possible, so that we.You could very quickly recognize what was different in the child with autism, from either their mother or father, having them in comparison, just like makes that sort of crank we were turning about very easy to turn. We've had issues in terms of being able to get, and I call it, we call them dangling dads.But dads that, you know, just haven't quite gotten it together and have found the time or found their kit to send that back in. And that has decreased the number of family units, mothers, fathers, and children with autism that we can look at. And so. has limited. Some of the analysis that we do on the other hand, as I said, we want to make sure everyone that contributes is able to contribute.So we have our analyses now include every single person who's contributed a saliva sample to SPARK, at least a, you know, saliva sample that's been sufficient to be able to sequence. So whether it's just one person or one person in their mother or one person and their father, everyone is represented in what SPARK does.Just a question, as I said, of what we can recognize I do want to call out and this may or may not be obvious to listeners, but I do want to call out. It is really important for everyone to be represented because of the number of types of autisms. But also I think it's an equity issue in terms of ancestral diversity.So where in the world. Your family came from, if they came from China, if they came from Brazil, if they came from Ghana, wherever in the world, they came from, it's really important because the genetic variants from our ancestors differ depending on where in the world you came from. And right now, in terms of genetics, about 80% of the genetic data we have as part of research comes from individuals from about 20% of the world's population.And so we are. Overrepresented for individuals of European ancestry, which means that in terms of being able to recognize those genetic factors, we do a pretty good job. If you're of European ancestry, we don't do nearly as good a job, though. If your family comes from other parts of the world and. Both in terms of equity and making sure that we don't increase this gap in terms of genomic medicine and utility of this information.It's really important to me that everyone gets the same shot at this. And that's part of, like I said, why we made this so easy for people. And I hope they'll take advantage of that because some people won't get this information any other way,Harry Glorikian: We need to be inclusive of everybody, but when I look at the trajectory and the, and the.How all of these technologies across a number of different areas, that seems to be a common theme is, you know, who accessed it first? Where do we have the most data and what do we need to do next? And I, I look at the, all these technologies as on an evolutionary scale, right? Where, where we're, we're continuing to add and how do we get to more people?How do we make it easier for people to participate, et cetera? Cause. When we were at applied Biosystems and there were sequencers right there. I mean, you could just, it was pretty easy to participate. Whereas for other people who don't have access or it's not as, I mean, if D'Souza at Illumina does what he wants to where he's, he's talking about a $60, whole genome.There'll be things that we'll be doing that we haven't even thought of yet. Wendy Chung: Absolutely. And we've thought of some of those things. So the next time you have me on, we'll talk about some of those others. But, but I, you know, in So, although there's the accessibility, I do think there are some issues, understandable issues about trust.And do I want you to have my genome? Do I trust you to have my genome? You know, could you do something Is some police officer going to arrest me or, you know, try and somehow plant evidence. That's going to be used against me in some way. So I think there are all sorts of reasons why certain members of our community don't feel comfortable with them.Participating and I totally get that. I think part of it is I want to make it easy for people. I also want to make sure and it's through SPARK that we're doing, this is to understand and have those individuals have a seat at the table, be able to address as many of those concerns as we have. So we can build that trust and build that, you know, shared vision and shared goal in terms of moving the science forward.And I say this and it's slightly different. I'm going to slightly digress, but I also, as a geneticist, for instance Treat patients for instance, who have cancer or have a family history of cancer. And I'll just very briefly share a story, which is that I had a patient who happened to be of African-American ancestry.And she actually through a very long I'll just long story short had a family history of breast and ovarian cancer. And although she did the sort of BRCA tests that some people talk about BRCA1 and 2, she did not really get the full. Understanding of the information from that test because she had a genetic variant that at the time wasn't recognized it happened to be a real true, what we call disease causing variant to increase the risk of breast and ovarian cancer.But it wasn't recognized because her community, her individuals from the same ancestry, weren't represented to be able to distinguish sort of the signal from the noise if you will. And so that's what happens in terms of, and she ultimately went on to develop. Metastatic cancer, unfortunately. And so there's this gap that has been evolving and actually gets wider and wider with the more that we depend on using genomic medicine, either to select the right medication or be able to decide what preventative treatments or what increased screening to do.There becomes a wider and wider gap between the haves and the have-nots. And I, I just want to make sure we narrow that gap. We get back to being equitable. Harry Glorikian: I totally agree. I mean, I have my own pet peeve stories about BRCA I mean, I was lucky enough to do I helped Myriad with some of their strategies and, you know and I got to learn a lot about their database versus everybody else's database.And so I have my pet peeves on where people should go and get their testing. But I also agree that being able to explain this to someone. Is not trivial. That person didn't fall off the turnip truck. Right. And the data is changing daily. I used to be able to turn on my computer and I'd be like, oh, I can keep track of that one and keep track of it.Now it's for forget it. If I don't have IT support. Hmm. And somebody who's been studying it it's, I don't want to say it's relatively impossible, but it's extremely daunting. To sort of keep up with what's going on. Wendy Chung: So let me just I'm going to stay on that note, although it's not directly SPARK related.There's some listener out there who would this'll resonate with your point of scalability and to be able to wrangle all of that changing interpretation of the data in real time is very important to me because like you said, there's a lot that we don't yet know what it means, not just related to autism, but related to a lot of the way our bodies function.And there needs to be a platform and informatics system that facilitates that you as an individual to your doctor would be great. But you also, as an individual can contribute to and engage in to be able to manage your own health. Harry Glorikian: So I have to tell you, I mean, after all the work I've done and everything that I've tried to write and so on and so forth, this whole idea that everybody has, that they're going to have their individual silos is to me, a bunch of malarkey, right?We've all seen that when you put all the mapping information and Google has it, it's an exquisite piece of, you know, useful database that you get you around tells you where you need to go, what you need to do. It's not. there aren't 50 of them or a hundred of them. I mean, in our world, if I think of everybody's individual silos, there's thousands of them.And it should be, I mean, the country itself needs to aggregate this. I know that medical professionals will be like, no, it's my data. It's not your data. It's the patient's data. And it should be aggregated. And by aggregation, we can gain more insight into it, but, you know, These are policy issues that every once in a while, I try to influence people on.But boy, they, they, the technology is moving much faster than the understanding of the people that are writing the policy and not to digress. But I think if we want to solve problems or at least gain a deeper understanding until we do that, I think it's just going to be chipping away except for programs like yours or certain companies that I know that are spending the money to.Build a massive data set that they can then sift through. But all of this work that you're doing is to diagnose the patient better, manage the patient, better, understand the progression of PA of the patient, but it's also to eventually I'm assuming design certain drugs or, or certain therapeutic interventions that, that, that w w where are you from?In that standpoint. Wendy Chung: Yep. So we are moving forward. It's not going to happen overnight, but I talk a lot about getting people to the starting line. So we have a sister study for SPARK called Simon Searchlight. That's actually, we've been doing that for about 10 years. That now is once you get a diagnosis, a genetic diagnosis, the point is then you've got a group of individuals that all share that same genetic diagnosis.You can learn from each other. You can learn from researchers. And to your point now, you know what starting line and what race you need to line up for. Right? Because you're in terms of a treatment or a support, it's likely to be specific. There may be some commonalities across genes, but in some cases, if you think about a gene therapy or gene editing or gene replacement or something like that, That is going to be at the level of specificity, at least at the gene.And in some cases, maybe even by the genetic variant. So in terms of doing that number one is that I do think this is going to be, I call it a step function mathematically, right? So there are going to be enabling technologies. And when certain enabling technologies and delivery systems are in place, they're going to be, it's not just going to be one condition.That's now treatable. It's going to be a whole class genetically of conditions that are treatable. And it's a matter of as modules popping in the right gene into that system and making sure that the window of opportunity for treatment is still open. But as we're doing that, it's important to me that even for conditions that are seemingly very rare, they're in the aggregate.Quite common. And there are a lot of lessons to be learned from each other as we're doing that. So it's kind of getting everyone lined up. We're starting to think about, and I don't want to put a timeframe on it, but it may be as soon as within the next year or two, that we'll be starting to actually use treatments.In some of the individuals, either in SPARK or Simon Searchlight with one of those genetic events that's amenable to some of these molecular technologies. We have a clinical trial for something called R-Baclofen that got shut down by COVID, but hopefully we'll be opening up again soon. And that will be it's a small molecule or a pill that you'll take.But for certain individuals with a particular group called 16P11.2 deletions, again, one genetically defined group. But that clinical trial, I hope will be opening up in later in 2021. So we are marching forward towards treatments. We also think of, as I said, supports for individuals.So it's not just about changing the person or giving them a drug. But thinking about, you know, what do you need? Is it that you need coaching in terms of how to, you know, ask someone out on a date, how to be able to interview for a job, how to, you know, be able to get your life together, to go off to college and live somewhat independently, you know, Things like that, that may be a little bit more difficult for certain individuals.But how do we deal with some of those things as well? All of these I think are going to be incredible opportunities. And like I said, a large part of what I do is try and de-risk all of this. So think about the research community. What does the research community need? What are we going to need for FDA registration?How can I make this easier, more accessible? Like how can I. What are the tools I can put in the toolkit so that if someone has got a hammer, I can point them to all of these nails out here that they can just start hammering one by one and be able to hopefully make a much bigger impact than they could if they just, you know, saw one nail that they could hit.But with this, like I said, it's not going to happen overnight. It's still, I think, you know, when I think back to the last year of what we've had in terms of molecular therapies, you know, things like Spinraza and spinal muscular atrophy have been truly revolutionized you know, what used to be for me, the most common genetic cause of death for infants is now something that we do with.Newborn screening and we have a one and done gene therapy. I mean, it's just remarkable. I, I never, in my wildest dreams 20 years ago would have thought that we would be there. And I think that's part of the, you know, that sort of vision, that way of thinking about things I wonder and hope that at some point in the not too distant future, we'll be able to identify kids.Early at a window of opportunity for treatment line them up for the right safe treatment, if they needed and be able to bend that curve, put them on a different trajectory than they might otherwise have been on. Harry Glorikian: I've spent time you know, talking to Robert Green about BabySeq and sequencing, you know, children and, and you're right.I mean, if I think about from the day we were starting the genome project to now We we've revolutionized some areas. I mean, things that were a death sentence or whatever have completely changed. I'm not sure the public or people fully appreciate that. That's why, when somebody writes a paper, the genomic sequencing hasn't had an impact.I, it just drives me nuts. Okay we've talked about the benefits of all this, but if you could say to. Why should people donate their genetic data? I want to want to see if we can get some of the listeners to touch some of the people that they know or at least get the word out.And then what, what can the rest of us do to help? Sure. Wendy Chung: So, so if you'd like to participate, the website is sparkforautism.org, sparkforautism.org, right there on that website, on that landing page, you just, there's a tab that says join us today. And that starts you on the process of being able to sign up for doing this.You can share that with a friend. Everyone in the United States is welcome who has we call it a professional diagnosis of autism. So in other words, a psychologist a doctor you know someone has officially said that they have autism, not just that. They think it's a possibility, but someone has really said that they do have autism and of any age.So it could be a two year old to a 50 year old. And then as I said, their family members, so that's in terms of doing it in terms of, like I said, the information that you get back from it, I do hope. This, this, I will say also as a practicing geneticist, this doesn't replace me in terms of wearing my hat as a doctor providing genetic information.So if you're a pregnant mom out there who has a son with autism, and you're worried about, you know, the risks to your baby right now see a medical doctor about this because it takes us a little while on the research side, I won't be able to get you a result a week later, it does take time. So, so we're not meaning to replace the medical system.But as you're doing this, I do hope you'll find it helpful. Like I said, to get some of your own personal information genetically about autism, and most importantly, it's to be represented that is that I don't know where the insight is going to come from. And I want to make sure that we have information that's useful to us.Everyone across the spectrum, whether it be by age, whether it be by gender, whether it be by where you live in the United States, whether it be by your gene. There's so many different dimensions and it changes over the life course that it's a big ask. I realize. But we are committed to doing this and I will say it's through the generosity of the Simons family and the Simons Foundationthat we're committed to this for the long run. I don't have to worry about will NIH fund this for another five-year cycle. I don't have to worry about the upturn or the downturn of the economy or fundraising for this year. This is one of the truths in life that I can say this is going to be around for the longterm.And so you don't have to worry that this is going to disappear or go down in flames or that, you know, your samples and your information are going to be stuck in a freezer or warehouse. And no one's going to pay attention to this. This is, and I've emphasized this, but. This is what's driving autism research in the United States.There are literally hundreds of researchers that are using this as the way to know better. And if you want to be easily in touch with those researchers, find the cutting edge information. This is an easy way to become an insider. So I hope you'll use the opportunity in whatever way suits you best, but definitely share it with a friend and hopefully you'll be able to get something out of this too.Harry Glorikian: No, this is, this is fascinating. I'm, I'm really glad that we have the opportunity to talk and expose the listeners to this because I think what you're doing as a process needs to be replicated in a number of different areas. And then at some point it would be interesting to have a portal that would potentially share and aggregate that information in a, in a way But I, cause I always think, you know, we just don't know what we don't know yet and there's gotta be a way to evolve this as it goes forward.So it was great to talk to you. As I said, I feel like I know you from the PBS show, but great to actually meet you in person and look forward to publishing the episode and, and, you know, getting people excited about this opportunity.Wendy Chung: Well, thanks for having me and helping to increase the awareness and thanks for what you do educating the public about what science and big data are about is so incredible to educate all of us so that we can make better decisions.Harry Glorikian: Excellent. Thank you.Harry Glorikian: That's it for this week's show. You can find past episodes of MoneyBall Medicine at my website, glorikian.com, under the tab “Podcast.” And you can follow me on Twitter at hglorikian.  Thanks for listening, and we'll be back soon with our next interview.

Dr Steve Unwin, Lecturer in Biosystems and Environmental Change at the University of Birmingham School of Biosciences in the UK, is a European specialist in Zoo Health Management. Steve starts introducing how he became into the field of veterinary science and conservation, his work in zoos and other facilities and his time as a veterinary officer and clinical manager at Chester Zoo. Steve thinks that conservation is not about animals, is but about people, and he highlights the importance of storytelling for conservation purposes.Steve shares his involvement with the Pan African Sanctuary Alliance veterinary programme, through which he also worked together with Sabrina. Steve is not only working with African primates but also with orangutans through the Orangutan Veterinary Advisory Group. He remarks on the importance of capacity building of local primate and wildlife veterinarians, scientists and conservation managers.Steve explains the differences between the One Health and the One Welfare approach and how it is key to work as an extensive network together. Sabrina and Steve discuss about the need for collaboration between veterinarians and other animal welfare or behaviour experts to get the best for the animals, and their interest in human wellbeing, the wellbeing of people caring for animals and its interconnectedness.Steve finishes with a story about animals being released back into the wild and one of his first surgery where he learned an important and lifelong message.Learn more about PASA HERELearn more about OVAG HERELearn more about One Health and One Welfare HERE Become a member of PAWS HERE

A fun but insightful conversation during 3DHEALS2020 with two inspiring entrepreneurs in 3D Bioprinting space, Tamer Mohamed (CEO and co-founder of Aspect Biosystems), and Mike Graffeo (CEO and co-founder of Fluidform). Aspect bio has just successfully completed its series A round, and Fluidform just successfully raised its seed round. Learn from Tamer and Mike on what startup CEOs' challenges, experiences, visions, and advice for the biofabrication and 3D printing space. Full conference video recording can be purchased here. Support the show (https://www.paypal.com/cgi-bin/webscr?cmd=_s-xclick&hosted_button_id=STF9STPYVE2GG&source=url)

Agricultural and Environmental Sciences Communication Major, Leanne Gamet talks with UNL Ph.D. Student Bridget Tripp. Bridget explains her studies in the Complex Biosystems program and the big data that is tied throughout. Find out more about her work with Harvard Med and Dilarium.

Tom O’Brien / AxionBioSystems, Inc. Tom O'Brien is the President and Chief Executive Officer of Axion BioSystems in Atlanta, GA, maker of life science instrumentation and medical diagnostic equipment. Since co-founding the company in 2008, he has led a team that has introduced two new products into the life science market. Prior to Axion, Tom […] The post Tom O’Brien and James Ross of Axion BioSystems, Inc. appeared first on Business RadioX ®.